Tiger Media (IDI) Reports Unaudited Financial Results for the First Nine Months of 2012

Tiger Media, Inc. (“Tiger Media”) (NYSE MKT:IDI) (NYSE MKT:IDI.WS), formerly known as SearchMedia Holdings Limited, one of China’s leading nationwide multi-platform media companies, today reported unaudited financial results for the nine months ended September 30, 2012.

Financial Highlights for the Nine Months ended September 30, 2012

• Revenue decreased 40% year-on-year from $45.5 million to $27.3 million.
• Operating profit increased from $2.2 million to $7.2 million year-on-year.
• Net profit increased from $1.1 million to $6.0 million year-on-year mainly attributable to one time gain on disposal of subsidiaries and gain from extinguishment of acquisition consideration.
• Acquisition consideration payable reduced from $23.2 million at year end 2011 to $5.7 million at September 30, 2012.
• The Company closed on two private placements pursuant to which the Company sold an aggregate of 7.0 million shares of the Company’s common stock at a price of $1.00 per share.
• The Company’s Convertible Note Holders converted $3.1 million in convertible notes into common shares at a price of $1.00 per share.
• After giving effect to the approximately $2.1 million of proceeds received from the warrant price reduction and exchange completed on December 26, 2012, shareholders’ equity would be $5.6 million and cash would increase to $9.4 million.

Unaudited Financial Results for the Nine Months ended September 30, 2012

Revenue decreased 40% to $27.3 million in the first nine months of 2012 from $45.5 million for the same period last year primarily due to the divestiture of Zhejiang Continental, Shenyang Jingli and Qingdao Kaixiang, the streamlining of Ad-Icon Shanghai’s non-profitable elevator business and the termination of our VIE structure.

Gross profit decreased year-on-year from $10.6 million in the same period last year to $3.1 million as a result of a decrease in revenue during the period, divestiture of Shenyang Jingli, Zhejiang Continental, Qingdao Kaixiang, and streamlining of the Ad-Icon Shanghai elevator business while still incurring contracted advertising space lease costs. Gross margin decreased to 11.4% from 23.3% in the same period last year due to higher concession costs, higher network expansion cost, higher percentage of agency business in advertising revenue, and recent subsidiaries separation and elevator business streamlining.

Total operating expenses (excluding divestment related gain) for the first nine months of 2012 were $7.1 million compared to $8.4 million for the prior year period as a result of business streamlining and management’s continued efforts to control costs. Sales and marketing expenses decreased 47% to $2.0 million from $3.8 million in the prior year period, primarily reflecting a proportional decrease in sales commissions as a result of lower revenue. General and administrative expenses increased 10% to $5.0 million from $4.6 million in the prior year period, reflecting an increase in agency expenses.

Operating profit was $7.2 million compared to $2.2 million due to the $11.1 million gain on disposal of subsidiaries and extinguishment of certain acquisition consideration payable. Net profit for the first nine months of 2012 was $6.0 million compared to $1.1 million in the prior year period due to a gain on the disposal of subsidiaries and the extinguishment of certain acquisition consideration payable.

Adjusted net loss for the first nine months of 2012 was $3.8 million compared with net profit of $1.2 million after excluding non-cash items such as the gain from the extinguishment of acquisition consideration payable of $3.0 million, the gain on disposal of subsidiaries of $8.1 million, the loss on abandonment of lease of $0.5 million, the loss on disposal of fixed assets of $0.4 million, and share based compensation of $0.4 million. Please refer to the non-GAAP reconciliation table provided at the end of the release for a period-over-period comparison of non-cash adjustments.

Earnout liabilities as of September 30, 2012 totaled $5.7 million down from $23.2 million at December 31, 2011. Additional reduction of the earnout liability is expected in fourth quarter of 2012. For the nine months ended September 30, 2012, the Company had a weighted average number of basic and diluted shares outstanding of 20.3 million shares. After giving effect to the approximate 1.7 million shares to be issued as a result of the December 2012 warrant exercise, the Company will have basic and diluted shares outstanding of approximately 30.1 million shares.

During the 2012 third quarter, the Company closed on two private placements with certain accredited investors pursuant to which the Company sold an aggregate of 7.0 million shares of the Company’s common stock at a price of $1.00 per share. Additionally during the 2012 third quarter, all of the Company’s investors from its February 2012 Convertible Note Offering agreed to convert their Convertible Notes (including accrued interest) into common shares at $1.00 per share.

As part of the Company’s initiative to divest non-performing businesses and based on a study of the performance and projections of Wuxi Ruizhong Advertising Co. Ltd. (“Wuxi Ruizhong”), the Company agreed to divest Wuxi Ruizhong back to its previous owners and eliminate the related earnout liability of $0.3 million, other liabilities of $0.3 million and income tax payable of $0.7 million. In connection with this divestment, the Wuxi founders returned to the Company for cancelation the 132,272 shares previously issued to them for settlement of the Company’s earnout obligations. As of November 30, 2012, Wuxi Ruizhong’s operating results will no longer form part of the Company’s consolidated financial statements. The Company believes that the cost savings from not carrying out the remaining earnout obligations pursuant to the acquisition agreement for Wuxi Ruizhong frees up the Company’s resources for use in other more promising opportunities.

Peter W.H. Tan, Chief Executive Officer of Tiger Media remarked, “The results of the nine months of 2012 shows a trend of decreased revenue for the Company as we focus on improving the margins and the bottom line and continue to streamline our business by closing unprofitable offices and divesting certain subsidiaries and eliminating the underlying earnout liability in order to pursue more accretive concession opportunities. These actions however, resulted in reduced performance in the first nine month of 2012. Going forward, we believe that we will create significant shareholder value through strategic, long term proprietary concessions with prominent partners. We have additional potential concessions and acquisition opportunities in our pipeline and we expect additional announcements shortly.

About Tiger Media

Tiger Media is a leading nationwide multi-platform media company and one of the largest operators of integrated outdoor billboard and in-elevator advertising networks in China. Tiger Media operates a network of high-impact billboards and one of China’s largest networks of in-elevator advertisement panels in 50 cities throughout China. Tiger Media’s core outdoor billboard and in-elevator platforms are complemented by its transit advertising platform, which together enable it to provide multi-platform, “one-stop shop” services for its local, national and international advertising clients. Learn more at www.tigermedia.com.cn.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts, including statements about Tiger Media’s beliefs and expectations, may constitute forward-looking statements as that term is defined by the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” “confident” and similar statements. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations.

Potential risks and uncertainties include, but are not limited to: whether the costs savings from the remaining earnout obligations of Wuxi will free up more Company resources for more promising opportunities; whether we will create significant shareholder value through large, long term proprietary concessions with prominent partners; whether the additional concessions in our pipeline will come to fruition and be beneficial; whether the additional concessions will allow the Company to become a larger and more profitable company resulting in improved cash flow and cost savings; and the risks that there are uncertainties and matters beyond the control of management, and other risks outlined in the Company’s filings with the U.S. Securities and Exchange Commission. Tiger Media cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Tiger Media does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.

TigerLogic (TIGR) Signs Definitive Agreement To Acquire Mobile App Publisher Storycode

The Acquisition of Storycode to Extend the Postano Social Visualization Platform into Mobile, Improving Fan Engagement for Brands

IRVINE, Calif., Dec. 28, 2012 /PRNewswire/ — TigerLogic Corporation (Nasdaq: TIGR) today announced that it has reached an agreement to acquire privately held Storycode, Inc., a mobile app publishing studio. TigerLogic plans to integrate Storycode’s technology into the Postano social visualization platform.

According to a November, 2012 McKinsey report ‘Capturing Business Value With Social Technologies,’ an in-depth analysis of four industry sectors that represent almost 20 percent of global industry sales suggests that social platforms can unlock $900 billion to $1.3 trillion in value in those sectors alone.  “With TigerLogic’s acquisition of Storycode, we believe we will be well positioned  to close the social media communications gap between consumers and brands.” said Richard Koe, TigerLogic ‘s Interim Chief Executive Officer.

Storycode’s mobile app publishing platform allows brands to easily, and quickly, create immersive mobile apps. “By combining Storycode’s mobile app platform with Postano, we can rapidly advance TigerLogic’s mission of creating compelling interactive experiences for brands to engage with their fans and customers.” said James McDermott, Storycode’s Chief Executive Officer.

Postano and Storycode:
With the integration of Postano, and Storycode, brands will have access to a new kind of social platform with unique mobile distribution capabilities. This new platform will allow brands to use original and fan-generated content to develop engaging experiences across web, events, and mobile environment. This means those responsible for brand affinity can drive improved consumer loyalty with visually based engagement in real-time. The Storycode platform is easy to manage and implement, leveraging existing content management systems, social platforms, and video channels, to create and populate content apps.

“We are excited about this new capability to offer our customers, and their fans, mobile app options that integrate with our Postano visualization platform and can be rapidly deployed to create engaging mobile experiences,” said Mr. Koe. “This past year, we’ve seen incredible momentum and adoption of Postano, from brands like Tommy Hilfiger, Nine West, Dell, the University of Oregon Athletic Department, and many others. Brands are integrating Postano into their websites, Facebook pages, and in retail spaces today, and they are asking us to deliver the same experience for their customers via the mobile channels. Storycode technology allows us to do that.”

Customer Profile: The University of Oregon Athletic Department
The University of Oregon provides the fans of its football team, Oregon Ducks, with a live, real-time peek inside its cutting edge social media command center, the Quack Cave, via GoDucks.com.

Interested members of the Oregon Ducks fan community can supplement their game event experience by consuming the team’s visualized social media content, either in real-time, or after the game as a way to recapture all of that event’s excitement. The University of Oregon uses Postano platform to deliver this experience, and as a result of the Storycode acquisition will be able to provide fans the same experience in a mobile environment.

“The Quack Cave, powered by Postano, enables its student volunteers to review, moderate and share the 150,000+ posts generated by fans every football game.  This has allowed the athletic department to facilitate increased social sharing and even more national buzz around Oregon Athletics,” said Craig Pintens, University of Oregon’s Senior Associate Athletic Director. “Taking what we do with Postano and re-creating that into an innovative mobile sharing platform is something we’ve asked for, and TigerLogic will be delivering. We think this will take our social media and marketing efforts to the next level of fan and brand engagement.”

In addition to its mobile technology platform, Storycode will add significant expertise to TigerLogic’s team in areas of user experience, data visualization, and creative services.

Closing of the acquisition is conditioned on customary conditions, including approval of the transaction by Storycode’s stockholders and certain third parties. The acquisition is expected to close early in TigerLogic’s fourth quarter of fiscal year 2013. TigerLogic intends to hold a conference call in connection with the closing of the transactions, which will be seperately announced when it is scheduled.

About Storycode, Inc.
Storycode is a mobile app studio located in Portland, Oregon. Led by James McDermott CEO and Justin Garrity CCO, Storycode has developed a mobile publishing platform that makes it easy for publishers and brands to create immersive, cross platform apps that leverage existing content management systems (CMS), and social networks. Storycode customers include Entrepreneur Media, The Independent, Mindjet, CBS, NBC, and Thomson Reuters. More information about Storycode can be found at http://www.storycode.com

About TigerLogic Corporation
TigerLogic Corporation (Nasdaq: TIGR) is a global provider of data management and application development solutions for enterprises that need to launch easy and cost-effective e-business initiatives. TigerLogic’s installed customer base includes more than 500,000 active users representing more than 20,000 customer sites worldwide, who rely on TigerLogic’s offerings for multidimensional database management, rapid application development, search enhancement, as well as content aggregation and syndication. Built on proven technology, TigerLogic helps control data and transform it into business intelligence and engagement. More information about TigerLogic and its products can be found at http://www.tigerlogic.com.

The foregoing release contains forward-looking information, including statements about the closing of the Storycode acquisition, the expected synergies from the transaction and the anticipated development of integrated products and capabilities. Any forward-looking statements are subject to risks and uncertainties, and actual results could differ materially due to several factors, including but not limited to TigerLogic’s ability to successfully integrate the Storycode technology and employees and to realize the anticipated synergies, the success of the combined companies research and development efforts to develop new products and to penetrate new markets, the market acceptance of the  new products and updates, technical risks related to such products and updates, TigerLogic’s ability to maintain market share for its existing products, the availability of adequate liquidity and other risks and uncertainties. Please consult the various reports and documents filed by TigerLogic with the U.S. Securities and Exchange Commission, including but not limited to the most recent reports on Form 10-K and Form 10-Q for factors potentially affecting TigerLogic’s future financial results. All forward-looking statements are made as of the date hereof and TigerLogic disclaims any responsibility to update or revise any forward-looking statement provided in this news release.

TigerLogic, Postano, yolink, Raining Data, Pick, mvDesigner, D3, mvEnterprise, mvBase, Omnis, and Omnis Studio are trademarks of TigerLogic Corporation. Storycode is a trademark of Storycode, Inc. All other trademarks and registered trademarks are properties of their respective owners.

magicJack (CALL) Expects to Post Over $39 Million in GAAP Revenue and Over $0.70 EPS

Company Expects to Exit 2012 With Lower Share Count of 18.8 Million Shares and $40 Million in Cash and Investments

WEST PALM BEACH, Fla. and NETANYA, Israel, Dec. 28, 2012 (GLOBE NEWSWIRE) — magicJack VocalTec, Ltd. (Nasdaq:CALL) (the “Company”), the Voice Experts and cloud communications leader that invented voice over IP (VoIP) and sold over ten million magicJacks^®, announces higher estimates for Q4 and full year 2012. For Q4, the Company expects to have over $0.70 per share of operating income. These estimates increased based on lower telecom expenses, higher receipts and a reduction in legal, advertising, media and other expenses. The Company had 19.3 million shares outstanding at end of Q3 2012, and cash and investments of $34.3 million. The Company has reduced share count by approximately 500,000 shares and increased cash and investments by $6 million since last quarter (Q3 2012). The Company expects to end this year with approximately 18.8 million shares outstanding and approximately $40 million in cash and investments, and continues to drastically reduce its telecom costs while increasing access charge collections.

Although the Company typically focuses on GAAP numbers, it wants its investors to clearly understand that the deferred revenue liabilities reported in Q3 2012 of $127.3 million will end up having a fraction of that amount of real cash outlay. In other words, under GAAP, deferred revenue liabilities are not cash liabilities. The Company’s liquidity and cash generation has been so large because deferred revenue liabilities required only a small cash outlay, and we expect the same pro rata outlays and possibly better in the future. In the past, the Company has not broken out many non-GAAP details, but intends to include more non-GAAP details in future earnings releases. The Company will continue to inform investors of any developments that may be deemed important during its buyback program. Operating income does not include one-time charges including charitable donations and other income.

magicJack CEO Dan Borislow stated, “Our results for 2012 will exceed expectations. We leave the year with little litigation and having added important new assets. Our future goals have been established with precise plans for achieving them for 2013. I want to thank our employees for a job well done and a special shout out to Greg Wood, Peter Russo, Kirill, Dr. Y.W. Sing, Jonathan, Bin, Mary, Greg, Shelby and the Boys.”

The company will host a conference call today for investors at 10:00 a.m. ET. Conference call details are as follows:

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements about our projected revenues, cash flows, strategy, future operations, new product introductions and customer acceptance, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. These factors include, among other things: changes to our business resulting from increased competition; any operational or cultural difficulties associated with the continuing integration of the businesses of VocalTec and YMax; potential adverse reactions or changes to business relationships resulting from the completion of the merger; unexpected costs, charges or expenses resulting from the merger; the ability of the combined Company to achieve the estimated potential synergies or the longer time it may take, and increased costs required, to achieve those synergies; our ability to develop, introduce and market innovative products, services and applications; our customer turnover rate and our customer acceptance rate; changes in general economic, business, political and regulatory conditions; availability and costs associated with operating our network; potential liability resulting from pending or future litigation, or from changes in the laws, regulations or policies; the degree of legal protection afforded to our products; changes in the composition or restructuring of us or our subsidiaries and the successful completion of acquisitions, divestitures and joint venture activities; and the various other factors discussed in the “Risk Factors” section of  our Annual Report on Form 10-K and other filings  with the Securities and Exchange Commission. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

magicJack® is a registered trademark of magicJack VocalTec Ltd. All other product or company names mentioned are the property of their respective owners.

About magicJack VocalTec Ltd.

magicJack VocalTec Ltd. (Nasdaq:CALL), the inventor of VoIP including the softphone and magicJack, has the goal of becoming the leading international provider of global voice over many platforms. The Company has achieved sales of over ten million of the easy-to-use, award-winning magicJack since the device’s launch in 2008, and has the use of over 30 patents, some dating to when the Company invented VoIP. It is the largest reaching CLEC (Competitive Local Exchange Carrier) in the United States in terms of area codes available and certification in number of states, and the network has historically had uptime of over 99.99 percent.

The VocalTec Communications Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8568

CONTACT: Kari Hernandez, INK for magicJack
         magicjack@ink-pr.com

Aeterna (AEZS) Granted Special FDA Protocol Assessment for Phase 3 Endometrial Cancer

Aeterna Zentaris Granted Special Protocol Assessment by the FDA for Phase 3 Registration Trial in Endometrial Cancer with AEZS-108

QUÉBEC CITY, Dec. 28, 2012 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that it has reached an agreement with the U.S. Food and Drug Administration (“FDA”) on a Special Protocol Assessment (“SPA”) for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.

“We are pleased with the agreement with the FDA which provides us with a clearly defined development and regulatory pathway for AEZS-108 in endometrial cancer”, stated Juergen Engel, PhD, President and CEO at Aeterna Zentaris. “AEZS-108’s innovative targeted approach could offer a new treatment option for women with endometrial cancer and provide the Company with a significant market opportunity.”

Study Design

This will be an open-label, randomized, multicenter Phase 3 trial conducted in North America and Europe, comparing AEZS-108 with doxorubicin as second line therapy for locally-advanced, recurrent or metastatic endometrial cancer. The trial will involve approximately 500 patients and the primary efficacy endpoint is improvement in median Overall Survival.

About Special Protocol Assessments (“SPA”)

The SPA process is a procedure by which the FDA provides official evaluation and written guidance on the design and size of proposed protocols that are intended to form the basis for a Biologics License Application (“BLA”) or New Drug Application (“NDA”). Final marketing approval depends on the results of efficacy, the adverse event profile and an evaluation of the benefit/risk of treatment demonstrated in the Phase 3 trial.

About AEZS-108

AEZS-108 represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin. AEZS-108 is the first intravenous drug in advanced clinical development that directs the chemotherapy agent specifically to Luteinizing Hormone Releasing Hormone (“LHRH”)-receptor expressing tumors, resulting in more targeted treatment with less damage to healthy tissue. The product has successfully completed Phase 2 studies for the treatment of ovarian and endometrial cancer and the Company is currently planning a Phase 3 trial in endometrial cancer under a Special Protocol Assessment. AEZS-108 is also in Phase 2 trials in prostate, breast and bladder cancer. AEZS-108 has been granted orphan drug designation by the FDA and orphan medicinal product designation from the European Medicines Agency for the treatment of ovarian cancer. Aeterna Zentaris owns the worldwide rights to AEZS-108.

About Endometrial Cancer

Endometrial cancer is the most common gynecologic malignancy and develops when abnormal cells amass to form a tumor in the lining of the uterus. It largely affects women over the age of 50 with a higher prevalence in Caucasians and a higher mortality rate among African Americans. Approximately one in 30 women is diagnosed with endometrial cancer every year. According to the American Cancer Society, 47,130 new cases of endometrial are expected to be diagnosed in the United States in 2012, and Data Monitor expects 35,600 new cases in    EU-G5 in 2013, with about 20% recurrent disease.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company’s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit www.aezsinc.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

Sonde Resources (SOQ) Farms Out 66% of Joint Oil Block Interest

CALGARY, ALBERTA — (Marketwire) — 12/28/12 — Sonde Resources Corp. (“Sonde” or the “Company”) (TSX:SOQ) (NYSE MKT:SOQ) (NYSE Amex:SOQ) announces that it has farmed out 66.67% of its interest in the Joint Oil Block to Viking Energy North Africa Limited (“Viking”), a private company. Sonde will receive the following consideration in connection with the farm out (all amounts are in U.S. Dollars):

--  Viking will pay Sonde in total a US $3 million non-refundable signature
    bonus; 

--  Viking will assume responsibility for the three well exploration
    commitment under the terms of the EPSA and fund 100% of the Joint Oil
    Block share of the Unit Plan of Development for the Zarat Field. The
    first well, Fisal, is to be drilled in 2013 along with the acquisition
    of seismic data covering the Hadaf prospect;

--  Viking will also provide to Sonde, prior to closing, the appropriate
    form of corporate guarantee with the agreed upon commercial terms, in
    order to secure the remaining work commitment under the terms of the
    EPSA;

--  Sonde will receive 20% of the cost recovery and profit share revenue
    until Sonde recovers US $70 million. After payout of all Viking
    expenditures, the revenue will be split 33.33% to Sonde and 66.67% to
    Viking; 

--  Sonde retains the option to fund its 33.33% share of two of the
    exploration wells; and

--  Any future discoveries will be shared 33.33% to Sonde and 66.67% to
    Viking.

This farm out is subject to the following conditions precedent:

--  Viking (or one of its affiliates) provides Sonde with a Corporate
    Guarantee sufficient to offset the current US $ 46.6 million guarantee
    for the potential penalties in respect of the three well drilling
    commitment and seismic ; and 

--  Joint Oil consents to the transfer of the interest to Viking and the
    naming of Viking as Operator of the Joint Oil Block under the EPSA.

As previously announced, the Joint Oil shareholders have now approved the second Exploration Phase extension and are reviewing the request to appoint Viking as operator of the Joint Oil Block. Jack Schanck, President and CEO said, “Sonde is very delighted to have the Viking Group as our partners in the Joint Oil Block development. Their expertise in FPSOs, their strategic relationship with the Thome Group and financial capability will allow our joint venture to develop the Zarat Field, and explore the potential of the Joint Oil Block. We look to this joint venture as a long-term relationship and commitment to the people of Tunisia and our Joint Oil partners. Sonde will plan a series of investor calls and meetings in early 2013 to fully expand on the opportunity this agreement represents.”

Sonde earlier indicated that it has reached a tentative agreement with PA Resources, the Zarat license holder, on the unitization principles of the Zarat Field, which is located to the south of the Joint Oil Block. The definitive agreement will include principles to the Unit Area, Unit Plan of Development Area and Tract Participation. The Unit Plan of Development is on track for submission to the Tunisian Authorities and approval by the end of the second quarter of 2013. A detailed reservoir technical evaluation undertaken jointly by Sonde/Viking and PA Resources is ongoing. Preliminary results performed by Sonde indicate that the gas recycling is a viable production option. This may advance the project to initial cash flow as early as 2015.

Conrad Clauson, Chairman of the Viking Group, indicated “that Viking Energy Group is very pleased to establish a long-term partnership with Sonde for the exploration and development of the Joint Oil Block. We look forward to working with our partners with the objective to develop liquid hydrocarbon resources contained in the Zarat field within the next two years using an FPSO vessel, followed by the monetization of the gas resources.”

“The Viking strategy for the Zarat field is to develop it through a two staged process, appraise and develop it with the objective to be able to convert the prospective resources into reserves and then tie in each future discovery into the same FPSO vessel as the one we believe should be used for the Zarat field development.”

“The development of the Zarat field will have strong operational synergies with the development of the Isis field located offshore Tunisia and also operated by the Viking Energy Group.”

“Viking will be working closely with all parties and our strategic industrial partner, Thome Oil and Gas Pte Ltd., which is a part of the Thome Group of Companies based in Singapore (www.thome.com.sg) to evaluate how we can fast track the development of the production and storage solution, minimize our capital expenditures and have cost effective operation.” Thome Oil and Gas Pte. Ltd. is an experienced FPSO/FSO operator which already has a presence in North Africa (Operations and maintenance management of AL Zaafrana FPSO in Egypt) and will also operate the Isis FPSO in Tunisia.”

Sonde Resources Corp. is a Calgary, Alberta, Canada based energy company engaged in the exploration and production of oil and natural gas. Its operations are located in Western Canada, and offshore North Africa. See Sonde’s website at www.sonderesources.com to review further detail on Sonde’s operations.

Forward Looking Information – This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws and “forward looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements include, among others, the proposed terms and conditions applicable to the pending farm out of a portion of the Company’s interest in the Joint Oil Block to Viking, the anticipated approval by Joint Oil of the deferral of the Company’s three exploratory well obligations relating to the Joint Oil Block into the second phase of the Exploration Period without payment of any penalty and the proposed unitization of the Zarat Field and the Joint Oil Block. There can be no assurance that the conditions precedent to the farm out agreement, including the approval of Joint Oil in respect of the deferral of exploratory well obligations and the consent to the transfer of the Company’s interests to Viking and the naming of Viking as Operator of the Joint Oil Block, will be received on terms acceptable to Sonde or at all or that Sonde will be able to reach a definitive agreement with respect to unitization with PA Resources. Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management’s expectations regarding negotiations with foreign governments and commercial parties, operating conditions, management’s expectations regarding future growth, plans for and result of drilling activity, market conditions, availability of capital, future commodity prices and differentials and capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, operational risks in development, exploration and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of reserve and resource estimates; the uncertainty of estimates and projections in relation to production; risks affecting Sonde’s ability to execute projects and market oil and natural gas; risks inherent in operating in foreign jurisdictions and negotiating with foreign governments and foreign commercial parties; the ability to attract and retain key personnel; and the inability to raise additional capital. Additional assumptions and risks are set out in detail in the Company’s Annual Information Form, available on SEDAR at www.sedar.com., and the Company’s annual reports on Form 40-F on file with the U.S. Securities and Exchange Commission.

Although management believes that the expectations reflected in the forward-looking information or forward-looking statements are reasonable, prospective investors should not place undue reliance on forward-looking information or forward-looking statements because Sonde can provide no assurance those expectations will prove to be correct. Sonde bases its forward-looking statements and forward-looking information on information currently available and do not assume any obligation to update them unless required by law.

Contacts:
Sonde Resources Corp.
Suite 3200, 500 – 4th Avenue S.W.
Calgary, Alberta, Canada T2P 2V6

Investor Relations
(403) 617-7728
(403) 216-2374 (FAX)

Jack Schanck
(403) 503 -7931

Array (ARRY) To Present At The Annual J.P. Morgan Healthcare Conference

BOULDER, Colo., Dec. 27, 2012 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Annual J.P. Morgan Healthcare Conference in San Francisco.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013.  For more information on Array, please go to www.arraybiopharma.com.

Smith & Wesson (SWHC) Expands Stock Repurchase Program

SPRINGFIELD, Mass., Dec. 27, 2012 /PRNewswire/ — Smith & Wesson Holding Corporation (NASDAQ Global Select: SWHC), a leader in firearm manufacturing and design, today announced that its Board of Directors has authorized an additional $15.0 million for common stock repurchases through June 30, 2013.

On December 6, 2012, the company announced that its Board of Directors approved a program to repurchase up to $20.0 million of the company’s outstanding shares of common stock from time to time until June 30, 2013.  The company has subsequently repurchased all of the initially authorized $20.0 million of common stock.

The amount and timing of any repurchases will depend on a number of factors, including price, trading volume, general market conditions, legal requirements, and other factors. Any shares of common stock repurchased under the program will be considered issued but not outstanding shares of the company’s common stock.  The company expects to fund the repurchase program using the company’s cash on hand and working capital.

About Smith & Wesson
Smith & Wesson Holding Corporation (NASDAQ Global Select: SWHC) is a U.S.-based leader in firearm manufacturing and design, delivering a broad portfolio of quality firearms, related products, and training to the global military, law enforcement, and consumer markets. The company’s brands include Smith & Wesson®, M&P™ and Thompson/Center Arms. Smith & Wesson facilities are located in Massachusetts and Maine. For more information on Smith & Wesson, call (800) 331-0852 or log on to www.smith-wesson.com.

Safe Harbor Statement
Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and we intend that such forward-looking statements be subject to the safe-harbor created thereby.  Such forward-looking statements include future repurchases of our common stock under our stock repurchase program, including the amount, time, and manner of repurchases, if any.  We caution that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by such forward-looking statements.  Such factors include risks that are detailed from time to time in our reports filed with the SEC, including our Form 10-K Report for the fiscal year ended April 30, 2012.

Contacts:
Liz Sharp, VP Investor Relations
Smith & Wesson Holding Corp.
lsharp@smith-wesson.com

Synergy (SGYP) Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome w/ Constipation

NEW YORK, Dec. 27, 2012 (GLOBE NEWSWIRE) — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that dosing has commenced in a Phase IIb clinical trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome (IBS-C).

This trial is being conducted at 70 sites in the United States and includes 350 patients with IBS-C who will be treated with one of four doses of plecanatide (0.3, 1.0, 3.0, or 9.0 mg) or placebo, taken once daily over a period of 12 weeks. PAREXEL International is the Contract Research Organization for the trial.

“We are pleased to be developing plecanatide for the treatment of IBS-C, a functional GI disorder of significant burden to patients,” said Gary S. Jacob, Ph.D., President and Chief Executive Officer of Synergy. “Synergy is about to complete an independent study of plecanatide in patients with chronic idiopathic constipation, and will be releasing top-line data from this trial early in January, 2013. We believe that plecanatide, which is an analog of the natural GI hormone uroguanylin, has the potential to produce an ideal combination of efficacy and safety for patients with IBS-C.”

Clinical Trial Design

Patients must meet the Rome III criteria for IBS as demonstrated by a history of recurrent abdominal pain or discomfort covering at least 3 days/month in the last 3 months associated with two or more of: 1) improvement with defecation, 2) onset associated with a change in frequency of stool, and 3) onset associated with a change in form (appearance) of stool. Patients must also meet the criteria for the IBS-C subtype, which is further characterized by stool pattern such that ≥ 25% of defecations are hard or lumpy stools and ≤ 25% of defecations are loose or watery stools.

The trial will measure the mean change in complete spontaneous bowel movements (CSBM’s) over the 12-week treatment period relative to patient’s baseline weekly CSBM rate established during the screening phase of the study. The trial will also evaluate spontaneous bowel movements (SBM’s) and daily abdominal pain, discomfort and bloating scores as well as the impact of plecanatide on disease-specific quality of life measures. For further information on the trial, please visit www.cibsstudy.com or the ClinicalTrials.gov listing (http://clinicaltrials.gov/ct2/show/NCT01429987?term=plecanatide&rank=1).

About Plecanatide

Plecanatide is a member of a new class of essentially non-systemic drugs, referred to as guanylate cyclase C (GC-C) agonists, that is currently in development to treat CIC and IBS-C. Plecanatide is a synthetic analog of uroguanylin, a natriuretic hormone that regulates ion and fluid transport in the GI tract. Orally-administered plecanatide binds to and activates GC-C receptors expressed on epithelial cells lining the GI mucosa, resulting in activation of the cystic fibrosis transmembrane conductance regulator (CFTR), and leading to augmented flow of chloride and water into the lumen of the gut. Activation of the GC-C receptor pathway is believed to facilitate bowel movements as well as producing other beneficial physiological responses including improvement in abdominal pain and inflammation. In animal models, oral administration of plecanatide promotes intestinal secretion and also ameliorates GI inflammation.

About Irritable Bowel Syndrome with Constipation (IBS-C)

Approximately 20 percent of the U.S. adult population, or one in five Americans, have symptoms of IBS, making it one of the most common disorders diagnosed by doctors. It occurs more often in women than in men (2-3:1 ratio), and it begins before the age of 35 in about 50 percent of people.

Irritable Bowel Syndrome (IBS) is characterized by recurrent episodes of abdominal pain and discomfort with associated alterations in bowel habits. Abdominal discomfort or pain is a universal feature required for the diagnosis of IBS and the predominant abnormal bowel pattern experienced by the patient leads to the subtyping of IBS as: diarrhea-predominant (D-IBS), constipation-predominant (C-IBS), or mixed IBS (M-IBS). Only IBS-C patients, are targeted for treatment with plecanatide.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy’s lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal (GI) hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers, a Phase IIa clinical trial in chronic idiopathic constipation (CIC) patients and has just completed a major Phase II/III clinical trial of plecanatide to treat CIC. Top-line results are expected to be released the first week of January 2013. Synergy intends to have an end of Phase II CIC meeting with the FDA in the first half of 2013. Synergy’s second GC-C agonist, SP-333, is currently in a Phase I clinical trial in volunteers. The development program for SP-333 is for treatment of inflammatory bowel diseases. More information is available at http://www.synergypharma.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. These forward-looking statements are based on Synergy’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Synergy’s Form 10-K for the year ended December 31, 2011, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Synergy does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

CONTACT: Media Contact
         Janet Skidmore
         Office:  215-658-4915
         Mobile:  215-429-2917
         skidmorecomm@earthlink.net

         Investor Contact

         Danielle Spangler
         The Trout Group
         synergy@troutgroup.com
         (646) 378-2924

Sonde (SOQ) Announces Approval Extension of North Africa Exploratory Obligations

CALGARY, ALBERTA — (Marketwire) — 12/27/12 — Sonde Resources Corp. (“Sonde” or the “Company”) (TSX:SOQ) (NYSE MKT:SOQ) (NYSE Amex:SOQ) confirms that Joint Oil’s Board and General Assembly have approved Sonde to enter the second Exploration Phase extending the exploration work program for the three exploratory wells obligation under the Exploration and Production Sharing Agreement (“EPSA”) to December 2015.

The Amending Agreement to the EPSA provides for a Second Phase Work Program as follows:

--  One Exploratory well must be drilled by the end of each year beginning
    in 2013 or will be subject to a US $15 million per well penalty; and  

--  Sonde will acquire 200 sq. km. of 3D seismic in the "B" subcontract area
    offshore Libya.

The seismic work is an additional obligation, as permitting did not allow the acquisition to take place during our seismic acquisition in 2012. Sonde continues to provide a Corporate Guarantee for the US $46.6 million potential penalty for noncompliance. The Corporate Guarantee declines by US $15 million as each well is drilled and $1.6 million when the 3D seismic is completed.

Jack Schanck, President and CEO, said, “Joint Oil has assisted Sonde by recognizing the increased costs and operational challenges in moving the Zarat Field development and exploratory effort forward by extending our obligations into the second phase of the exploration period. We are grateful to Joint Oil and its shareholders to allow us to move forward and develop the Block’s potential.”

Sonde Resources Corp. is a Calgary, Alberta, Canada based energy company engaged in the exploration and production of oil and natural gas. Its operations are located in Western Canada, and offshore North Africa. See Sonde’s website at www.sonderesources.com to review further detail on Sonde’s operations.

Forward Looking Information- This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws and “forward looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management’s expectations regarding negotiations with foreign governments and commercial parties. Actual results could differ materially due to a number of factors, including, without limitation, market conditions; risks inherent in operating in foreign jurisdictions and negotiating with foreign governments and foreign commercial parties; delays or changes in plans with respect to exploration or development projects or capital expenditures; risks affecting Sonde’s ability to execute projects and market oil and natural gas; and the inability to raise additional capital to pursue projects. Additional assumptions and risks are set out in detail in the Company’s Annual Information Form, available on SEDAR at www.sedar.com, and the Company’s annual reports on Form 40-F on file with the U.S. Securities and Exchange Commission. Although management believes that the expectations reflected in the forward-looking information or forward-looking statements are reasonable, prospective investors should not place undue reliance on forward-looking information or forward-looking statements because Sonde can provide no assurance those expectations will prove to be correct. Sonde bases its forward-looking statements and forward-looking information on information currently available and do not assume any obligation to update them unless required by law.

Contacts:
Sonde Resources Corp.
Investor Relations
(403) 617-7728
(403) 216-2374

Sonde Resources Corp.
Suite 3200, 500- 4th Avenue S.W.
Calgary, Alberta, Canada T2P 2V6

UBPS (UBPSW) Announces Transaction Update

Inter Parfums (IPAR) Signs an Exclusive License Agreement for Alfred Dunhill Fragrances

Inter Parfums, Inc. (NASDAQ GS: IPAR) today announced that it has entered into a ten-year exclusive worldwide fragrance license to create, produce and distribute perfumes and fragrance-related products under the Alfred Dunhill Limited (“dunhill”) brand. The agreement commences on April 3, 2013 and replaces a previous license agreement with Procter & Gamble that terminates on April 3, 2013. Inter Parfums will take over production and distribution of the existing Alfred Dunhill fragrance collections. Sales of current fragrances are planned for Spring 2013 and a new men’s scent is contemplated for 2014.

The house of Alfred Dunhill was established in 1893 and since that time has been dedicated to providing high quality men’s luxury products, with core collections offered in menswear, leather goods and accessories. The brand has global reach through a premium mix of self-managed retail outlets, high-level department stores and specialty retailers. Known for its commitment to elegance and innovation and being a leader of British men’s style, the brand continues to blend innovation and creativity with traditional craftsmanship.

Jean Madar, Chairman and CEO of Inter Parfums, Inc. stated, “We are enthusiastic about collaborating with this premier British brand and building the Alfred Dunhill fragrance enterprise into a major aspirational fragrance brand. Upon assuming responsibility for the brand, we will fine tune the current fragrance portfolio, which includes fragrances dating from 1934 to 2011. The new men’s scent planned for a 2014 launch will be supported by a distribution strategy that recognizes and utilizes Alfred Dunhill’s luxury positioning, along with brand appropriate marketing materials and a media campaign.”

Eraldo Poletto, CEO of Alfred Dunhill LTD stated, “We are proud to be partnering with Inter Parfums and look forward to working together to grow and develop our global fragrance business.”

About Inter Parfums:

In the nearly 30 years since its founding, Inter Parfums, Inc. has been selected as the fragrance and beauty partner for a growing list of brands that include Burberry, Lanvin, Jimmy Choo, Van Cleef & Arpels, Montblanc, Paul Smith, Boucheron, S.T. Dupont, Balmain, Karl Lagerfeld, Repetto, Alfred Dunhill, Anna Sui, Gap, Banana Republic, Brooks Brothers, bebe, Betsey Johnson, and Nine West. Inter Parfums is known for innovation, quality and its ability to capture the genetic code of each brand in the products it develops, manufactures and distributes in over 100 countries worldwide.

Statements in this release which are not historical in nature are forward-looking statements. Although we believe that our plans, intentions and expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such plans, intentions or expectations will be achieved. In some cases you can identify forward-looking statements by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” and “would,” or similar words. You should not rely on forward-looking statements because actual events or results may differ materially from those indicated by these forward-looking statements as a result of a number of important factors. These factors include, but are not limited to, the risks and uncertainties discussed under the headings “Forward Looking Statements” and “Risk Factors” in Inter Parfums’ annual report on Form 10-K for the fiscal year ended December 31, 2011 and the reports Inter Parfums files from time to time with the Securities and Exchange Commission. Inter Parfums does not intend to and undertakes no duty to update the information contained in this press release.

magicJack (CALL) Modifies Product For Wi-Fi, LTE Internet Access, DECT, Multi-Line Phones

magicJack Modifies Newest Product to Accommodate Wi-Fi, LTE Internet Access, DECT, Multi-Line Phones and Other Possibilities Off One Device

WEST PALM BEACH, Fla. and NETANYA, Israel, Dec. 26, 2012 (GLOBE NEWSWIRE) — magicJack VocalTec, Ltd. (Nasdaq:CALL) (the “Company”), the Voice Experts and cloud communications leader that invented voice over IP (VoIP) and sold over ten million magicJacks^®, announced today that the newest product has been modified to include two USB slots, one USB plug, a SD micro slot, one RJ11 jack and one RJ45 jack. With LTE 4G progressing so quickly in the United States and throughout the world, the Company modified the newest product for a few months to accelerate the ability to offer discounted Internet access to new and existing customers using this device besides other functions and features. This will provide many people their first opportunity to take advantage of high-speed Internet access.

magicJack will announce the new product name in 2013 and expects the new product to be offered in early Q2 2013. Incredibly, it will be only be about slightly larger than the magicJack PLUS and will offer high definition (HD) voice. The Company expects additional, exciting new products to follow in 2013 utilizing our second new chip of 2013. This is a 55nm chip designed for portable use and includes a super scalar one Ghz CPU and much larger GB DDR2 or DDR3 memory as well as over 25 other functions. The Company expects to continue to offer the magicJack PLUS as its price-leading model as it has proven to be very reliable and desirable, with extremely good sales recorded in December. It is no wonder that the magicJack PLUS continues to do so well, as the Company will soon announce a major award granted to magicJack, with the Company scoring on top of five different metrics being awarded the top consumer VoIP company.

Dan Borislow adds, “With assets nobody else has we will continue to dominate and grow our space. This is the power of what we are building and the patents and IP we have built up. This has been a breakout year not only financially, but we have developed and planned our future. Our growth is predicated on locking some deals up and executing on our plans. We do not need one more unique idea to be very successful and grow the value of our Company for years to come. I think 2013 will be the year people understand what we are building, our technology and our vast opportunities. Our newest products will be our best inventions and will dwarf what we have done with magicJack to date.”

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements about our projected revenues, cash flows, strategy, future operations, new product introductions and customer acceptance, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. These factors include, among other things: changes to our business resulting from increased competition; any operational or cultural difficulties associated with the continuing integration of the businesses of VocalTec and YMax; potential adverse reactions or changes to business relationships resulting from the completion of the merger; unexpected costs, charges or expenses resulting from the merger; the ability of the combined Company to achieve the estimated potential synergies or the longer time it may take, and increased costs required, to achieve those synergies; our ability to develop, introduce and market innovative products, services and applications; our customer turnover rate and our customer acceptance rate; changes in general economic, business, political and regulatory conditions; availability and costs associated with operating our network; potential liability resulting from pending or future litigation, or from changes in the laws, regulations or policies; the degree of legal protection afforded to our products; changes in the composition or restructuring of us or our subsidiaries and the successful completion of acquisitions, divestitures and joint venture activities; and the various other factors discussed in the “Risk Factors” section of  our Annual Report on Form 10-K and other filings  with the Securities and Exchange Commission. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

magicJack® is a registered trademark of magicJack VocalTec Ltd. All other product or company names mentioned are the property of their respective owners.

About magicJack VocalTec Ltd.

magicJack VocalTec Ltd. (Nasdaq:CALL), the inventor of VoIP including the softphone and magicJack, has the goal of becoming the leading international provider of global voice over many platforms. The Company has achieved sales of over ten million of the easy-to-use, award-winning magicJack since the device’s launch in 2008, and has the use of over 30 patents, some dating to when the Company invented VoIP. It is the largest reaching CLEC (Competitive Local Exchange Carrier) in the United States in terms of area codes available and certification in number of states, and the network has historically had uptime of over 99.99 percent.

The magicJack VocalTec Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10116

CONTACT: Investor Relations
         Andrew MacInnes, President
         561-749-2255
         ir@magicJack.com

         Media Relations
         Kari Hernandez, INK for magicJack
         512-382-8982
         magicjack@ink-pr.com

Nova (NVMI) Receives Over $15 Million Orders From Several Leading Foundries

REHOVOT, Israel, December 26, 2012 /PRNewswire/ —

Nova Measuring Instruments Ltd. (NASDAQ: NVMI) a leading provider of optical metrology solutions to the semiconductor process control market, announced today that several leading foundries recently placed over 15 million dollars of orders in aggregate as part of their production ramp up and development efforts for future technology nodes.

The orders include Nova’s most advanced integrated and stand alone metrology tools and NovaMARS® modeling software with extended capabilities to assist customers to overcome the advanced process requirements in light of shrinking geometries and complicated 3D structuring. The tools will support manufacturing ramp up and capacity increase in multiple process steps as well as development efforts for their next generation technology nodes.

“We are delighted with this large order stream from the world leading foundries that continue to ramp aggressively in order to meet the demand for smart phone, tablets and mobile computing markets. Our integrated and stand-alone solutions portfolio optimally supports the challenging needs of foundries at 28nm and 20nm with future extendibility to 1X technology nodes,” said Eitan Oppenhaim, Executive Vice President of Global Business at Nova.

The company expects to ship the tools during the current and next quarters.

About Nova: Nova Measuring Instruments Ltd. develops, produces and markets advanced integrated and stand alone metrology solutions for the semiconductor manufacturing industry. Nova is traded on the NASDAQ & TASE under the symbol NVMI. The Company’s website is http://www.nova.co.il.

This press release contains forward-looking statements within the meaning of safe harbor provisions of the Private Securities Litigation Reform Act of 1995 relating to future events or our future performance, such as statements regarding trends, demand for our products, expected deliveries, transaction, expected revenues, operating results, earnings and profitability. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in those forward looking statements. These risks and other factors include but are not limited to: our dependency on two product lines; the highly cyclical nature of the markets we target; our inability to reduce spending during a slowdown in the semiconductor industry; our ability to respond effectively on a timely basis to rapid technological changes; our dependency on OEM suppliers; cyber security risks; risks related to open source technologies; our ability to retain our competitive position despite the ongoing consolidation in our industry; risks associated with our dependence on a single manufacturing facility; our ability to expand our manufacturing capacity or marketing efforts to support our future growth; our dependency on a small number of large customers and small number of suppliers; our dependency on our key employees; risks related to changes in our order backlog; risks related to the financial, political and environmental instabilities that may affect our sales in Asia; risks related to our intellectual property; changes in customer demands for our products; new product offerings from our competitors; changes in or an inability to execute our business strategy; unanticipated manufacturing or supply problems; changes in tax requirements; changes in customer demand for our products; risks related to currency fluctuations and risks related to our operations in Israel. We cannot guarantee future results, levels of activity, performance or achievements. The matters discussed in this press release also involve risks and uncertainties summarized under the heading “Risk Factors” in Nova’s Annual Report on Form 20-F for the year ended December 31,2011 filed with the Securities and Exchange Commission on March 28, 2012. These factors are updated from time to time through the filing of reports and registration statements with the Securities and Exchange Commission. Nova Measuring Instruments Ltd. does not assume any obligation to update the forward-looking information contained in this press release.

Company Contact:
Dror David, Chief Financial Officer
Nova Measuring Instruments Ltd.
Tel: +972-73-229-5833
E-mail: info@nova.co.il
http://www.nova.co.il

Investor Relations Contacts:
Ehud Helft / Kenny Green
CCG Investor Relations
Tel: +1-646-201-9246
E-mail: nova@ccgisrael.com

Western Copper and Gold (WRN) has experienced unusual trading activity

VANCOUVER, Dec. 26, 2012 /PRNewswire/ – Western Copper and Gold Corporation (“Western” or the “Company”) (TSX:WRN; NYSE MKT:WRN) has no comment on unusual trading activity on the NYSE MKT (the “Exchange”).

In view of the unusual market activity in the Company’s stock, the Exchange has contacted the Company in accordance with its usual practice.  Western stated that its policy is not to comment on unusual market activity.

ABOUT WESTERN COPPER AND GOLD CORPORATION

Western Copper and Gold Corporation is a Vancouver-based exploration and development company with significant copper, gold and molybdenum resources and reserves.  The Company has 100% ownership of the Casino Project located in the Yukon Territory. The Casino Project is one of the world’s largest open-pit gold, copper, silver and molybdenum deposits. For more information, visit www.westerncopperandgold.com.

On behalf of the board,

“Dale Corman”
F. Dale Corman
Chairman & CEO

Cautionary Disclaimer Regarding Forward-Looking Statements and Information

Certain of the statements and information in this press release constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities laws.  Forward-looking statements and information generally express predictions, expectations, beliefs, plans, projections, or assumptions of future events or performance and do not constitute historical fact.  Forward-looking statements and information tend to include words such as “may,” “expects,” “anticipates,” “believes,” “targets,” “forecasts,” “schedules,” “goals,” “budgets,” or similar terminology.  Forward-looking statements and information herein include, but are not limited to, statements with respect to resource and reserve estimates.  All forward-looking statements and information are based on Western’s or its consultants’ current beliefs as well as various assumptions made by and information currently available to them.  Although management considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect.  Forward-looking statements and information are inherently subject to significant business, economic, and competitive uncertainties and contingencies and are subject to important risk factors and uncertainties, both known and unknown, that are beyond Western’s ability to control or predict.  Actual results and future events could differ materially from those anticipated in forward-looking statements and information.  Examples of potential risks are set forth in Western’s most recently filed Form 40-F with the U.S. Securities and Exchange Commission and its most recently filed Annual Information Form with the Canadian Securities Administrators as of the date of this press release.  Accordingly, readers should not place undue reliance on forward-looking statements or information.  Western expressly disclaims any intention or obligation to update or revise any forward-looking statements and information whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.

Diodes (DIOD) to Acquire BCD Semiconductor Manufacturing Limited

Diodes Incorporated (Nasdaq: DIOD), a leading global manufacturer and supplier of high-quality application specific standard products within the broad discrete, logic and analog semiconductor markets, and BCD Semiconductor Manufacturing Limited (“BCD Semiconductor” or “BCD”) (Nasdaq: BCDS), a leading analog integrated device manufacturer incorporated in the Cayman Islands, today announced that Diodes has entered into an Agreement and Plan of Merger to acquire BCD.

Highlights of the transaction include:

• Combined trailing twelve months (“TTM”) reported revenue of approximately $750 million with significant cross-selling opportunities;
• Expected to be immediately accretive to Diodes’ GAAP earnings per share;
• Strengthens Diodes’ analog product portfolio by expanding its standard linear and power management offerings;
• Broadens Diodes’ presence in Asia through BCD’s strong local market position in China;
• Enhances market and margin expansion opportunities by leveraging Diodes’ cost-effective manufacturing and packaging capabilities;
• Expands design and manufacturing capabilities for increased capacity and scale; and
• Expected to result in revenue, operating and cost synergies.

At the effective date of the merger, each American Depository Share, which represents six ordinary shares of BCD, will be converted into the right to receive $8.00 in cash, without interest. The aggregate consideration will be approximately $151 million. The boards of both companies have approved the transaction, which is still subject to approval by BCD’s shareholders, as well as other customary closing conditions and regulatory approvals. The transaction is expected to close late in the first quarter of 2013 or early in the second quarter.

Commenting on the transaction, Dr. Keh-Shew Lu, President and Chief Executive Officer of Diodes, stated, “This proposed acquisition underscores Diodes’ strategy to expand our market and growth opportunities through select strategic acquisitions. This transaction will greatly enhance our analog product portfolio by expanding our standard linear and power management offerings, including AC/DC and DC/DC solutions for power adapters and chargers, as well as other electronics products. BCD’s established presence in Asia with a particularly strong local market position in China offers Diodes even greater penetration of the consumer, computing and communications markets. Likewise, Diodes can achieve increased market penetration for BCD’s products by leveraging our global customer base and sales channels. In addition, BCD has in-house manufacturing capabilities in China, as well as a cost-effective development team that can be deployed across multiple Diodes’ product families. We will also be able to apply Diodes’ packaging capabilities and expertise to BCD’s products in order to improve cost efficiencies, utilization as well as product mix.”

Dr. Lu concluded, “Diodes has a successful track record of combining businesses to achieve revenue expansion, cost reductions and improved profitability. BCD employees are a key asset, and we look forward to integrating them into the Diodes family as we work closely with our customers to familiarize them with our new expanded offerings, while continuing to provide exceptional service and support.”

Commenting on the proposed acquisition, Mr. Chieh Chang, Chief Executive Officer of BCD Semiconductor, said, “We are pleased to have reached this agreement because we believe that BCD Semiconductor becoming a part of Diodes represents a compelling opportunity for our customers, employees and shareholders. This transaction provides liquidity at a significant premium for our shareholders and the combined company greatly strengthens the analog offerings and market opportunities for our customers.”

Atlas Technology Group LLC and Duff & Phelps LLC acted as financial advisors and Sheppard Mullin Richter & Hampton LLP acted as legal counsel to Diodes Incorporated. RBC Capital Markets LLC acted as exclusive financial advisor and Covington & Burling LLP acted as legal counsel to BCD Semiconductor.

Conference Call and Slide Presentation Information

Diodes will host a conference call on Thursday, December 27, 2012 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time). This conference call will be broadcast live over the Internet with a slide presentation and can be accessed by all interested parties on the Investor section of Diodes’ website at http://www.diodes.com. On the call Dr. Keh-Shew Lu, Diodes’ President and Chief Executive Officer, Rick White, Diodes’ Chief Financial Officer, Mark King, Diodes’ Senior Vice President of Sales and Marketing, Laura Mehrl, Diodes’ Director of Investor Relations, and Mr. Chieh Chang, Chief Executive Officer of BCD Semiconductor, will discuss the proposed acquisition. Investors and analysts are invited to participate on the call. To listen to the live call, please go to the Investor section of Diodes website and click on the Conference Call link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

For those unable to participate during the live broadcast, a replay will be available shortly after the call and will be available on Diodes’ website for approximately 60 days. The replay number is (888) 286-8010 with a pass code of 87654471. International callers should dial +1 (617) 801-6888 and enter the same pass code at the prompt.

Further details of the transaction and arrangement are set out in Diodes’ Current Report on Form 8-K filed with the Securities and Exchange Commission on December 26, 2012.

About BCD Semiconductor

BCD Semiconductor Manufacturing Limited is a leading analog integrated device manufacturer, or IDM, based in China, specializing in the design, manufacture and sale of power management integrated circuits. BCD’s broad product portfolio targets primarily rapidly growing, high volume market segments such as mobile phones, LCD televisions and monitors, personal computers, adapters and chargers. As an IDM, BCD integrates product design and process technology to optimize product performance and cost, and offers system-level solutions with quality and reliability. BCD’s China-based operations also give it immediate access to the fast growing electronics industry in Asia, enabling BCD to align its product development efforts with market trends and provide timely and effective technical support to its customers. For more information, please visit http://www.bcdsemi.com.

About Diodes Incorporated

Diodes Incorporated (Nasdaq: DIOD), a Standard and Poor’s SmallCap 600 and Russell 3000 Index company, is a leading global manufacturer and supplier of high-quality application specific standard products within the broad discrete, logic and analog semiconductor markets. Diodes serves the consumer electronics, computing, communications, industrial, and automotive markets. Diodes’ products include diodes, rectifiers, transistors, MOSFETs, protection devices, functional specific arrays, single gate logic, amplifiers and comparators, Hall-effect and temperature sensors; power management devices, including LED drivers, DC-DC switching and linear voltage regulators, and voltage references along with special function devices, such as USB power switches, load switches, voltage supervisors, and motor controllers. Diodes’ corporate headquarters, logistics center, and Americas’ sales office are located in Plano, Texas. Design, marketing, and engineering centers are located in Plano; San Jose, California; Taipei, Taiwan; Manchester, England; and Neuhaus, Germany. Diodes’ wafer fabrication facilities are located in Kansas City, Missouri and Manchester, with two manufacturing facilities located in Shanghai, China, and two joint venture facilities located in Chengdu, China, as well as manufacturing facilities located in Neuhaus and Taipei. Additional engineering, sales, warehouse, and logistics offices are located in Fort Worth, Texas; Taipei; Hong Kong; Manchester; Shanghai; Shenzhen, China; Seongnam-si, South Korea; Tokyo, Japan; and Munich, Germany, with support offices throughout the world. For further information, including SEC filings, visit Diodes’ website at http://www.diodes.com.

Forward-Looking Statements

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such statements include statements as to: the expected benefits of the acquisition, including the acquisition being immediately accretive; the efficiencies, cost savings, revenues, and enhanced product offerings, market position, and design and manufacturing capabilities of Diodes after the acquisition; and other statements identified by words such as “estimates,” “expects,” “projects,” “plans,” “will” and similar expressions. Potential risks and uncertainties include, but are not limited to, such factors as: the possibility that the transaction may not be consummated, including as a result of any of the conditions precedent; the risk that BCD’s business will not be integrated successfully into Diodes’; the risk that the expected benefits of the acquisition may not be realized, including the realization of the accretive effect of the acquisition; the risk that BCD’s standards, procedures and controls will not be brought into conformance within Diodes’ operation; difficulties coordinating Diodes’ and BCD’s new product and process development, hiring additional management and other critical personnel, and increasing the scope, geographic diversity and complexity of Diodes’ operations; difficulties in consolidating facilities and transferring processes and know-how; the diversion of our management’s attention from the management of our business; we may not be able to maintain our current growth strategy or continue to maintain our current performance, costs and loadings in our manufacturing facilities; risks of domestic and foreign operations, including excessive operation costs, labor shortages, higher tax rates and our joint venture prospects; unfavorable currency exchange rates; our future guidance may be incorrect; the global economic weakness may be more severe or last longer than we currently anticipated; and other information detailed from time to time in Diodes’ filings with the United States Securities and Exchange Commission.

Recent news releases, annual reports and SEC filings are available at Diodes’ website: http://www.diodes.com and BCD’s website: http://www.bcdsemi.com. Written requests may be sent directly to Diodes or BCD, or they may be e-mailed to: diodes-fin@diodes.com or ir@bcdsemi.com.

Chembio (CEMI) Receives FDA Approval for DPP(R) Point-of-Care HIV 1/2 Rapid Test

MEDFORD, N.Y., Dec. 21, 2012 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq:CEMI),a leader in point-of-care diagnostic tests for infectious diseases, announces receipt of approval from the U.S. Food and Drug Administration (FDA) to market the Company’s Dual Path Platform^® (DPP^®) HIV 1/2 assay for the rapid, point-of-care (POC) detection of HIV-1/2 antibodies in either oral fluid or blood samples. This determination follows a review of Chembio’s Premarket Approval (PMA) application and marks the first FDA approval of a diagnostic assay utilizing the Company’s patented Dual Path Platform^® technology. DPP^® enables samples to bind directly with target analytes before detection reagents are introduced to visualize the test results, and can improve accuracy compared with the current lateral flow HIV test technologies.

“We are very proud to receive FDA approval to market our DPP^® HIV 1/2 Assay, which allows us to commercialize a POC oral fluid rapid diagnostic test that we believe has superior performance compared with the only other oral fluid HIV rapid test on the market,” noted Lawrence Siebert, Chembio’s Chief Executive Officer. “With more than 1.2 million Americans estimated to be living with HIV and approximately 20% of them unaware they are infected with the virus, rapid HIV tests are playing a critical role in the U.S., as they have globally, to help identify those with HIV and to prevent disease transmission. In addition, the market for these tests is expected to grow significantly with the recent recommendations by the U.S. Preventive Services Task Force to mandate insurance reimbursement for routine HIV testing.”

Chembio’s DPP^® point-of-care HIV 1/2 Assay detects antibodies to HIV-1 and HIV-2 in oral fluid, fingerstick whole blood, venous whole blood, serum or plasma samples, and provides a simple “reactive/non-reactive” result. In a multi-site clinical study of approximately 2,800 patients across five clinical settings, including a pediatric hospital, the diagnostic sensitivity of the assay to detect HIV infection resulted in sensitivity of 99.8% for fingerstick samples; 99.9% for venous whole blood, serum and plasma samples; and 98.9% for oral fluid samples. The specificity of the assay was 100% for fingerstick specimens; and 99.9% for oral fluid, venous whole blood, plasma and serum samples. The test is intended to be used in the preliminary diagnosis of patients with HIV in point-of-care settings such as public health and other clinics, hospital emergency rooms and physician offices.

The DPP^® point-of-care HIV 1/2 Assay is the only rapid test in the U.S. that does not use lateral flow or other older flow-through technologies. DPP^® HIV 1/2 is approved to detect HIV in patients two years of age and older, which is also a differentiating feature compared with all other rapid assays that are approved only to detect HIV in patients 13 years of age and older. DPP^® HIV 1/2 delivers visual results within 15 minutes, is simple to use, requires minimal sample size, has a shelf life of 24 months and does not require refrigeration. DPP^® HIV 1/2 features a comfortable swab for collecting oral fluid samples and provides sharp, distinct test lines due to the DPP^® technology. In addition, a proprietary sample collection system enables each sample to be contained in a convenient, closed collection vial, or Sampletainer™, which may provide additional sample for repeat testing, allowing greater testing flexibility over other systems that do not have separate sample collection or that use open vials for stirring blood samples.

“As we finalize our commercial strategy for the launch of this new DPP^® assay in the U.S, we will be conducting and submitting our Clinical Laboratory Improvement Amendments (CLIA) waiver trials in order to establish the quality standards for our laboratory testing that provide for the accuracy, reliability and timeliness of patient tests results regardless of where the tests are performed,” added Mr. Siebert. “We plan to make this submission during the first half of 2013 and expect to launch DPP^® HIV 1/2 in the U.S. during the second half of 2013.”

For more information about the Company’s DPP^® point-of-care HIV 1/2 Rapid Assay, Chembio has animated video, poster presentations and publications available on its website at: http://chembio.com/products/human-diagnostics/dpp-hiv-12-assay/.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio’s two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical Innovations, Inc.). Chembio markets its HIV STAT-PAK^® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors.  Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform^® (DPP^®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP^®. Headquartered in Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485. For additional information, please visit the Company’s website at www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements, which are estimates only, reflect management’s current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio’s ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio’s products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio’s success are more fully disclosed in Chembio’s most recent public filings with the U.S. Securities and Exchange Commission.

CONTACT: Chembio Diagnostics
         Susan Norcott
         (631) 924-1135, ext. 125
         snorcott@chembio.com

         LHA
         Anne Marie Fields
         (212) 838-3777
         AFields@lhai.com
         @LHA_IR_PR

Lucas Energy (LEI) Announces Completion of $4 Million Asset Sale

HOUSTON, Dec. 21, 2012 (GLOBE NEWSWIRE) — Lucas Energy, Inc. (NYSE MKT:LEI), an independent oil and gas company (the “Company” or “Lucas”), today announced that the Company has completed the sale of a 0.77% net royalty interest in certain assets owned by the Company within the Baker Deforest Unit, located in Gonzales and Dewitt Counties, Texas, for $4 million.

On December 20, 2012, Ryan J. Morris was appointed as Chairman of the Board of Directors (J. Fred Hofheinz resigned as Chairman, but still remains on the Board as a Director).

Additionally, on December 20, 2012, the Company amended and restated its Bylaws, to among other things, make such Bylaws more stockholder friendly. The amendments include reducing the required ownership percentage of stockholders which is required to call a special meeting of stockholders to at least 10% of all shares entitled to vote at the proposed special meeting (down from 30%). The Company believes that these changes increase its shareholders’ ability to participate in the direction of the Company, and further bring the Company’s Bylaws in line with similarly sized companies.

A more detailed description of the asset sale and the changes affected by the amendments to the Bylaws can be found in the Company’s Form 8-K filing, filed with the Securities and Exchange Commission on December 21, 2012.

The Company would also like to update the marketplace as to the current status of certain previously reported lawsuits and other proceedings affecting the Company.

Specifically, the Company is pleased to report that it has: negotiated a 60 day stay of the lawsuit filed by Seidler Oil & Gas, L.P., to allow for the discussion of a settlement between the parties; provided a proposal for settlement to Knight Capital Americas LLC (as successor in interest to Knight Capital America, L.P.), in an effort to settle the lawsuit previously filed by Knight against the Company; and that the Company is currently in the process of attempting to reopen settlement discussions with Nordic Oil USA I, LP (“Nordic”), in connection with the Company’s previously announced default in the payment of the $22 million note payable to Nordic (due in November 2012) and Nordic’s subsequent filing of a lawsuit against the Company.

Finally, while the Company appreciates all of its shareholders and their input, a significant number of shareholders, brokers and other parties have contacted the Company over the past several days, and while the Company is working to provide as much information as possible in more frequent communications, the Company is simply unable to timely respond due to its current focus on addressing operating and efficiency issues. The Company appreciates your understanding and patience.

About Lucas Energy, Inc.

Lucas Energy, Inc., a Nevada corporation, is an independent oil and gas company based in Houston, Texas. The Company acquires underdeveloped oil and gas properties, restores production to the properties, and looks for underlying value. Currently, the Company is active in the Austin Chalk, Eagle Ford, Eaglebine, and Buda trends. Our goal for the current year is production and revenue growth, and expansion of our asset base using joint ventures.

For more information on this and other activities of the Company, please visit the Lucas Energy web site at www.lucasenergy.com.

The Lucas Energy logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4192

Company Website:

www.lucasenergy.com

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Act”) and Section 21E of the Securities Act of 1934, as amended (the “Exchange Act”). In particular, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements and are subject to the safe harbor created by these Acts. Any statements made in this news release about an action, projection, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Statements regarding future drilling and production are subject to all of the risks and uncertainties normally incident to the exploration and development of oil and gas. These risks include, but are not limited to, completion risk, dry hole risk, price volatility, reserve estimation risk, regulatory risk, potential inability to secure oilfield service risk as well as general economic risks and uncertainties, as disclosed in the Company’s SEC filings including its Form 10-K and Form 10-Q’s. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct its own forward-looking statements, except as required by law, or those prepared by third parties that are not paid for by the Company. The Company’s SEC filings are available at http://www.sec.gov.

CONTACT: Anthony C. Schnur, CEO
         tschnur@lucasenergy.com
         (713) 528-1881

Rainmaker (RMKR) Announces Sale of Manila Call Center to Shore Solutions

CAMPBELL, CA — (Marketwire) — 12/21/12 — Rainmaker Systems, Inc. (NASDAQ: RMKR), a leading global cloud e-Commerce company, today announced the sale of its Manila call center to Shore Solutions, Inc. on December 17, 2012.

Rainmaker decided to divest its Manila call center, as the operation no longer fits the long-term strategic plans of the company. For continuity and continued reach in the region, part of the agreement with Shore is to continue to utilize some of the key services we utilize today.

“We embarked on the sale process earlier this year and are very pleased to complete the sale of our Manila operations in the fourth quarter,” said Rainmaker Chief Financial Officer Timothy Burns. “The sale will allow us to continue to hone our strategic focus on maximizing SMB revenue for our clients with a leading e-Commerce platform supported by global customer assist agents.”

The sale will result in increased gross margins and have a positive cash flow impact and is an important step in Rainmaker’s tightening focus on cloud e-Commerce enhanced by customer assist agents.

About Rainmaker

Rainmaker is an e-Commerce software company that helps multi-national companies address the B2B market by maximizing sales revenue for their products and services. The Rainmaker e-Commerce platform can be enhanced with Rainmaker customer assist agents to maximize revenue and customer satisfaction through the entire customer life cycle.

For more information, visit www.rainmakersystems.com or call 800-631-1545.

NOTE: Rainmaker Systems and the Rainmaker logo are registered with the U.S. Patent and Trademark Office. All other service marks or trademarks are the property of their respective owners.

CONTACT:

Timothy Burns
Chief Financial Officer
Rainmaker Systems, Inc.
(512) 949-6021

TORM (TRMD) Financial Calendar 2013

COPENHAGEN, Denmark, Dec. 21, 2012 (GLOBE NEWSWIRE) —

Announcement no. 43 / 21
December 2012
TORM financial calendar 2013
Page 1 of 1

TORM expects to issue financial statements and convene its Annual General Meeting on the following dates in 2013:

• 28 February 2013 Deadline for shareholder submissions to the Annual General Meeting
• 13 March 2013 Annual Report 2012
• 11 April 2013 Annual General Meeting
• 8 May 2013 First quarter 2013 results
• 15 August 2013 First half 2013 results
• 5 November 2013 Nine months 2013 results

Financial reports are expected to be published before 09:00 CET on the respective dates.

Contact TORM A/S

C. Soegaard-Christensen, IR, tel.: +45 3076 1288
Tuborg Havnevej 18
DK-2900 Hellerup, Denmark
Tel.: +45 3917 9200 / Fax: +45 3917 9393
www.torm.com

About TORM

TORM is one of the world’s leading carriers of refined oil products as well as a significant player in the dry bulk market. The Company operates a fleet of approximately 110 modern vessels in cooperation with other respected shipping companies sharing TORM’s commitment to safety, environmental responsibility and customer service.

TORM was founded in 1889. The Company conducts business worldwide and is headquartered in Copenhagen, Denmark. TORM’s shares are listed on NASDAQ OMX Copenhagen (ticker: TORM) and on NASDAQ in New York (ticker: TRMD). For further information, please visit www.torm.com.

Safe Harbor statements as to the future

Matters discussed in this release may constitute forward-looking statements. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and statements other than statements of historical facts. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although TORM believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, TORM cannot guarantee that it will achieve or accomplish these expectations, beliefs or projections. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward- looking statements include the strength of the world economy and currencies, changes in charter hire rates and vessel values, changes in demand for “tonne miles” of oil carried by oil tankers, the effect of changes in OPEC’s petroleum production levels and worldwide oil consumption and storage, changes in demand that may affect attitudes of time charterers to scheduled and unscheduled dry-docking, changes in TORM’s operating expenses, including bunker prices, dry-docking and insurance costs, changes in the regulation of shipping operations, including requirements for double hull tankers or actions taken by regulatory authorities, potential liability from pending or future litigation, domestic and international political conditions, potential disruption of shipping routes due to accidents and political events or acts by terrorists.

Risks and uncertainties are further described in reports filed by TORM with the US Securities and Exchange Commission, including the TORM Annual Report on Form 20-F and its reports on Form 6-K.

ChinaNet (CNET) Sponsors Business Forum in Quanzhou

BEIJING, Dec. 21, 2012 (GLOBE NEWSWIRE) — ChinaNet Online Holdings, Inc. (Nasdaq:CNET) (the “Company” or “ChinaNet”), a leading B2B (business to business) Internet technology company focusing on providing online-to-offline (“O2O”) sales channel expansion services for small and medium-sized enterprises (“SMEs”) and entrepreneurial management and networking services for entrepreneurs in the People’s Republic of China, today announced that the Company participated as a sponsoring organizer of the Quanzhou Business Forum on December 17, 2012.

The inaugural Quanzhou Business Forum was organized by various business and local government leaders to address ways to help local small businesses prosper. Many business owners in the apparel and footwear industries are struggling with the slowdown in demand for their products caused by the recent deceleration global economic growth. ChinaNet, a leader in sales channel expansion services for SMEs, was invited to provide their expertise and possible solutions. ChinaNet Chairman Handong Cheng participated in a series of panel discussions, along with Quanzhou Economic and Trade Commission Director Huang Guofu, and Managing Director Ma Yue from RYO JI Technical Corporation, a ChinaNet customer. Executives from more than 30 enterprises such as Hongxing Erke Group, Fujian Force Clothing Co., Ltd., Quanzhou Yicheng Garment Co., Ltd. also attended the event.

“We are delighted to discuss ways to collaborate with the Quanzhou Economic and Trade Commission,” said George Chu, Chief Operating Officer of ChinaNet. “Quanzhou has a vibrant business culture, with 76 publicly listed companies, over 50,000 small businesses, including 1,500 companies with annual sales in excess of 100 million RMB ($15 million USD), looking for a trusted service provider to help them grow. We will work hand in hand with the Quanzhou Economic and Trade Commission and other local government authorities to jointly promote the development of SMEs.”

About ChinaNet Online Holdings, Inc.

The Company, a parent company of ChinaNet Online Media Group Ltd., incorporated in the BVI (“ChinaNet”), is a leading B2B (business to business) Internet technology company focusing on providing O2O (online to offline) sales channel expansion service for small and medium-sized enterprises (SMEs) and entrepreneurial management and networking service for entrepreneurs in China. The Company, through certain contractual arrangements with operating companies in the PRC, provides Internet advertising and other services for Chinese SMEs via its portal websites, 28.com, Liansuo.com and Chuangye.com, TV commercials and program production via China-Net TV, and in-house LCD advertising on banking kiosks targeting Chinese banking patrons. Website: http://www.chinanet-online.com.

Safe Harbor

This release contains certain “forward-looking statements” relating to the business of ChinaNet Online Holdings, Inc., which can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “estimates” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including business uncertainties relating to government regulation of our industry, market demand, reliance on key personnel, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. These forward-looking statements are based on ChinaNet’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting ChinaNet will be those anticipated by ChinaNet. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the Company) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. ChinaNet undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

CONTACT: MZ North America
         Ted Haberfield, President
         Tel: +1-760-755-2716
         Email: thaberfield@mzgroup.us
         Web: www.mzgroup.us

Avino (ASM) Announces $5 Million Credit Facilty With Caterpillar Finance

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 12/20/12 — Avino Silver & Gold Mines Ltd. (TSX VENTURE:ASM)(NYSE MKT:ASM)(BERLIN:GV6)(FRANKFURT:GV6) (“Avino” or “the Company”) is pleased to announce that its Mexican subsidiary COMPANIA MINERA MEXICANA DE AVINO, S.A. DE C.V. has entered into a master credit facility with CATERPILLAR CREDITO, S.A. DE C.V., SOFOM, ENR (“Caterpillar Finance”) for up to US $5 million.

The credit facility bears interest at rates ranging from 0% to 4.95% per annum. Equipment leased under the credit facility has terms of 18 months to 60 months. These terms are dependent on the Company’s requirements and equipment acquired.

The Company is very pleased about the new credit facility arrangement with Caterpillar Finance as it will help the Company to advance its current operations at San Gonzalo and to reopen the Avino Mine. With the credit facility in place, the Company has initiated the acquisition of the following pieces of mining equipment and expects to receive them by December 31, 2012 or shortly thereafter; the equipment being acquired for delivery before the end of the year represents about a third of the credit facility:

--  Caterpillar 420F Backhoe loader
--  Caterpillar R1600 Scoop tram
--  Oldenburg underground rock drill.

About Avino

Founded in 1968, Avino’s mission is to create shareholder value through profitable organic growth at the historic Avino property near Durango, Mexico. We are committed to managing all business activities in an environmentally responsible and cost-effective manner, while contributing to the well-being of the community in which we operate.

Our primary goal is to become a significant low cost primary silver producer. Our specific objectives are to achieve full time commercial production as soon as possible, expand resources, reserves and the mines output as well as to identify, explore and develop new targets on the property.

ON BEHALF OF THE BOARD

David Wolfin, President & CEO

This release contains statements that are forward-looking statements and are subject to various risks and uncertainties concerning the specific factors disclosed under the heading “Risk Factors” and elsewhere in the Company’s periodic filings with Canadian securities regulators. Such information contained herein represents management’s best judgment as of the date hereof based on information currently available. The Company does not assume the obligation to update any forward-looking statement.

Safe Harbor Statement – This news release contains “forward-looking information” and “forward-looking statements” (together, the “forward-looking statements”) within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995, including our belief as to the extent and timing of various studies including the PEA, and exploration results, the potential tonnage, grades and content of deposits, timing and establishment and extent of resources estimates. These forward-looking statements are made as of the date of this news release and the dates of technical reports, as applicable. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. While we have based these forward-looking statements on our expectations about future events as at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements.

Such factors and assumptions include, among others, the effects of general economic conditions, the price of gold, silver and copper, changing foreign exchange rates and actions by government authorities, uncertainties associated with legal proceedings and negotiations and misjudgments in the course of preparing forward-looking information. In addition, there are known and unknown risk factors which could cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Known risk factors include risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in metal prices; title matters; uncertainties and risks related to carrying on business in foreign countries; environmental liability claims and insurance; reliance on key personnel; the potential for conflicts of interest among certain of our officers, directors or promoters of with certain other projects; the absence of dividends; currency fluctuations; competition; dilution; the volatility of the our common share price and volume; tax consequences to U.S. investors; and other risks and uncertainties. Although we have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. We are under no obligation to update or alter any forward-looking statements except as required under applicable securities laws.

Cautionary Note to United States Investors – The information contained herein and incorporated by reference herein has been prepared in accordance with the requirements of Canadian securities laws, which differ from the requirements of United States securities laws. In particular, the term “resource” does not equate to the term “reserve”. The Securities Exchange Commission’s (the “SEC”) disclosure standards normally do not permit the inclusion of information concerning “measured mineral resources”, “indicated mineral resources” or “inferred mineral resources” or other descriptions of the amount of mineralization in mineral deposits that do not constitute “reserves” by SEC standards, unless such information is required to be disclosed by the law of the Company’s jurisdiction of incorporation or of a jurisdiction in which its securities are traded. U.S. investors should also understand that “inferred mineral resources” have a great amount of uncertainty as to their existence and great uncertainty as to their economic and legal feasibility. Disclosure of “contained ounces” is permitted disclosure under Canadian regulations; however, the SEC normally only permits issuers to report mineralization that does not constitute “reserves” by SEC standards as in place tonnage and grade without reference to unit measures.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts:
Avino Silver & Gold Mines Ltd.
David Wolfin
President & CEO
604.682.3701
604.682.3600 (FAX)
ir@avino.com

Atossa Genetics (ATOS) Announces Third Quarter 2012 Financial Results

SEATTLE, WA — (Marketwire) — 12/20/12 — Atossa Genetics, Inc. (NASDAQ: ATOS) today announced financial results for the third quarter of 2012, ended September 30, 2012.

“During the third quarter of 2012, we successfully completed our initial public offering of 800,000 shares at $5.00 per share, the midpoint of our price range. The proceeds from the IPO will enable us to accelerate the national roll-out of our first FDA-cleared and marketed product, the ForeCYTE Breast Health Test for breast cancer risk assessment,” stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO. “Our IPO was the only biotech IPO priced in the month of November and was priced in the immediate aftermath of Hurricane Sandy. I believe this is a testament to the strength of our business model and the significant revenue and earnings potential of Atossa Genetics over the next several years as we pursue the further commercialization of the ForeCYTE and ArgusCYTE tests with the 5,000-strong launch team through our marketing partner, Diagnostics Testing Group, LLC, the commercialization of two new tests in 2013, and the advancement of our intraductal therapeutics program to safely and effectively treat pre-cancerous breast lesions.”

Third Quarter 2012 Results

Total revenues for the third quarter of 2012 were $105,576, comprising $104,011 in diagnostic testing services and $1,565 in product sales, versus no revenues for the third quarter of 2011. The ForeCYTE and ArgusCYTE tests were launched through a field experience trial beginning in December 2011 and are expected to be rolled out nationally starting in early 2013.

Gross margin for the third quarter was 86 percent on gross profit of $90,499.

Operating expenses are comprised of selling, general and administrative (SG&A) expenses and research and development. For the third quarter of 2012, total operating expenses were $1.23 million versus $1.27 million for the third quarter of 2011.

Net loss for the third quarter ended September 30, 2012, was $1.14 million, or ($0.10) per share, versus a net loss of $1.27 million, or ($0.11) per share, for the year-ago quarter.

As of September 30, 2012, the Company had cash and cash equivalents of $418,570 versus $1.91 million at the end of December 2011. The company completed its IPO in November 2012, raising $4.0 million in gross proceeds prior to expenses and net proceeds of approximately $3.5 million.

Corporate Highlights

• Two FDA-cleared products launched through a field experience trial: ForeCYTE Breast Health Test for breast cancer risk assessment and ArgusCYTE Breast Health Test for detection of circulating breast tumor cells. Two additional tests are slated for launch in 2013: FullCYTE, designed to assess the individual breast ducts for pre-cancerous changes in women previously identified to be at high risk for breast cancer, and NextCYTE, designed to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer.
• Wholly owned, CLIA-Certified Laboratory, the National Reference Laboratory for Breast Health, established in Seattle.
• The Company completed its Initial Public offering of 800,000 shares at $5.00 per share on November 14, 2012, raising $4.0 million in gross proceeds before expenses and net proceeds of approximately $ 3.5 million.
• Entered into a co-exclusive marketing agreement with Diagnostics Testing Group, LLC, (DTG) for the supply and distribution of the ForeCYTE Breast Health System under the DTG Clarity brand for the sale and placement of the Clarity branded ForeCYTE product line with leading medical distributors. Collectively, these distributors have over 5,000 employee sales representatives and/or independent sales representatives selling their products.
• Entered into an agreement with MultiPlan, Inc. for diagnostic laboratory testing involving Atossa’s tests. Approximately 20 percent of Americans are covered by MultiPlan. Atossa will participate in the MultiPlan, PHCS and PHCS Savility Networks. The agreement will give MultiPlan’s participating providers and their patients access to Atossa’s tests. Atossa anticipates that the agreement with MultiPlan will help ensure that more doctors and their patients have access to the ForeCYTE and ArgusCYTE Breast Health Tests and that patients will receive insurance reimbursement for the laboratory costs associated with these tests.
• Sponsored the first inaugural steering committee meeting of the International Society for Cancer Risk Assessment and Management (ISC-RAM). The ISC-RAM is first society focused on advancing the knowledge of cancer risk assessment and education globally.
• Presented at the 2nd Annual Cancer Genome Summit. The presentation focused on breast cancer prevention through the diagnosis and treatment of the abnormal cells that are the precursors of cancer.
• Hired Christopher Destro as Vice President of Sales and Marketing. Mr. Destro is an industry veteran with over 16 years of successful sales and client management expertise within the clinical sector of diagnostic biotechnology.
• Atossa will present at the following upcoming conferences: OneMedForum on Tuesday, January 8, 2013, at 4:00 pm Pacific Time in San Francisco; Biotech Showcase on Wednesday, January 9, 2013, at 10:00 am Pacific Time in San Francisco; and the Personalized Medicine World Conference on Monday, January 28, 2013, in Mountain View, CA.

About Atossa Genetics, Inc.

Atossa Genetics, Inc., The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a “liquid biopsy” for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa’s plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa’s products and services, the use of proceeds from Atossa’s initial public offering, statements regarding the status of the
going concern qualification of Atossa’s financial statements by its auditors, the ability of Atossa to fund its planned activities, the market demand for and acceptance of Atossa’s products and services, uncertainty relating to Atossa’s future revenues and profitability, the timing for a national launch of Atossa’s diagnostic tests, and other risks detailed from time to time in the Atossa’s final prospectus, dated November 7, 2012, filed with the U.S. Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

-TABLES FOLLOW-

                           ATOSSA GENETICS, INC.
                       (A DEVELOPMENT STAGE COMPANY)
                        CONSOLIDATED BALANCE SHEETS

                                               September 30,   December 31,
                    Assets                          2012           2011
                                               -------------  -------------
                                                (Unaudited)     (Audited)
Current Assets

  Cash and cash equivalents                    $     418,570  $   1,910,821

  Restricted cash                                    250,000      1,000,000
  Accounts receivable                                175,408          1,224
  Prepaid expense                                     39,975         31,184
  Rental deposits                                      1,500          2,200
                                               -------------  -------------

    Total Current Assets                             885,453      2,945,429
                                               -------------  -------------

Fixed Assets
  Furniture and Equipment, net                        67,497         80,467
                                               -------------  -------------
    Total Fixed Assets                                67,497         80,467
                                               -------------  -------------

Other Assets
  Security deposit                                    36,446          5,157

  Intangible assets, net                           4,703,078         40,841
                                               -------------  -------------
    Total Other Assets                             4,739,524         45,998
                                               -------------  -------------

    Total Assets                               $   5,692,474  $   3,071,894
                                               =============  =============

     Liabilities and Stockholders' Equity

Current Liabilities

  Line of Credit                               $     250,000  $   1,000,000
  Accounts payable                                    72,100         64,766

  Accrued expenses                                 1,888,344        442,329
  Note payable - related party                        80,453          5,078
                                               -------------  -------------

  Total Current Liabilities                        2,290,897      1,512,173
                                               -------------  -------------

Stockholders' Equity
  Preferred stock - $.001 par value;
   10,000,000 shares authorized, 0 shares
   issued and outstanding                                  -              -
  Common stock - $.001 par value; 75,000,000
   shares authorized, 12,119,367 shares issued
   and outstanding                                    12,119         11,257

  Additional paid-in capital                      11,415,761      6,200,520

  Accumulated deficit                             (8,026,303)    (4,652,056)
                                               -------------  -------------

    Total Stockholders' Equity (Deficit)           3,401,577      1,559,721
                                               -------------  -------------

    Total Liabilities and Stockholders' Equity $   5,692,474  $   3,071,894
                                               =============  =============

                           ATOSSA GENETICS, INC.
                       (A DEVELOPMENT STAGE COMPANY)
                   CONSOLIDATED STATEMENTS OF OPERATIONS
                                (UNAUDITED)

                                                                From April
              For The Three Months       For The Nine Months     30, 2009
                     Ended                     Ended            (Inception)
                  September 30,             September 30,         Through
            ------------------------  ------------------------   September
                2012         2011         2012         2011      30, 2012
            -----------  -----------  -----------  -----------  -----------

Revenue

  Diagnostic
   Testing
   Service  $   104,011  $         -  $   376,696  $         -  $   376,696

  Product
   Sales          1,565            -        6,690            -        8,190

            -----------  -----------  -----------  -----------  -----------
    Total
     Revenue    105,576            -      383,386            -      384,886
            -----------  -----------  -----------  -----------  -----------

Cost of
 Revenue

  Diagnostic
   Testing
   Service       (9,000)           -      (29,985)           -      (29,985)

  Product
   Sales              -            -            -            -       (5,164)

            -----------  -----------  -----------  -----------  -----------
    Total
     Cost of
     Revenue     (9,000)           -      (29,985)           -      (35,149)
            -----------  -----------  -----------  -----------  -----------

Loss on
 Reduction of
 Inventory
 to LCM          (6,077)           -      (29,884)           -     (121,910)
            -----------  -----------  -----------  -----------  -----------

    Gross
     Profit      90,499            -      323,517            -      227,827
            -----------  -----------  -----------  -----------  -----------

Selling
 expenses       (87,704)           -     (281,971)           -     (455,026)
General and
 Administrative
 expenses    (1,138,467)  (1,274,189)  (3,405,198)  (2,231,906)  (7,766,497)

            -----------  -----------  -----------  -----------  -----------
    Total
    operating
    expenses (1,226,171)  (1,274,189)  (3,687,169)  (2,231,906)  (8,221,523)
            -----------  -----------  -----------  -----------  -----------

     Operating
      Loss   (1,135,672)  (1,274,189)  (3,363,652)  (2,231,906)  (7,993,694)

Interest
 Income              46        2,267        1,219        3,428        6,588

Interest
 Expense         (7,756)        (758)     (11,816)      (8,388)     (38,947)
            -----------  -----------  -----------  -----------  -----------

    Net Loss
     before
     Income
     Taxes   (1,143,382)  (1,272,680)  (3,374,249)  (2,236,866)  (8,026,053)

    Income
     Taxes            -            -            -            -          250
            -----------  -----------  -----------  -----------  -----------

Net Loss    $(1,143,382) $(1,272,680) $(3,374,249) $(2,236,866) $(8,026,303)
            ===========  ===========  ===========  ===========  ===========

Loss per
 common
 share -
 basic and
 diluted    $     (0.10) $     (0.11) $     (0.30) $     (0.27) $     (1.05)
            ===========  ===========  ===========  ===========  ===========
Weighted
 average
 shares
 outstanding
 basic &
 diluted     11,256,867   11,256,867   11,256,867    8,394,219    7,657,400
            ===========  ===========  ===========  ===========  ===========

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:

Atossa Genetics, Inc.
Steven C. Quay, M.D., Ph.D., FCAP
Chairman, President and CEO of Atossa Genetics and
Director of the National Reference Laboratory for Breast Health
800-351-3902
Email Contact

Matthew D. Haines (Investors and Media)
Managing Director
MBS Value Partners
212-710-9686
Email Contact

Venaxis (APPY) Appoints Senior Diagnostics Executive to Board of Directors

CASTLE ROCK, Colo., Dec. 20, 2012 /PRNewswire/ — Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced the appointment of Susan A. Evans, Ph.D., FACB, Vice President, Scientific Affairs for Beckman Coulter, to the Company’s Board of Directors effective January 1, 2013.  Dr. Evans, a 30-year veteran of the in vitro diagnostics industry, has developed numerous successful diagnostic tests over the course of her career.  In addition, she is highly respected within the industry, as evidenced by her past selection as President of the American Association of Clinical Chemistry (AACC), one of the industry’s lead professional organizations.  Dr. Evan’s experience will greatly benefit Venaxis as the company completes the development and regulatory clearance for and executes the launch of APPY1, and enhances its product portfolio.

Steve Lundy, President and CEO of Venaxis, stated, “We are excited to welcome Dr. Evans to our Board.  We expect 2013 to be a transformational year for Venaxis and Dr. Evans’ experience developing and launching in vitro diagnostic products will be very beneficial as we develop the market for APPY1 and look to develop next generation assays.”

Dr. Evans stated, “I believe APPY1 potentially fulfills a significant diagnostic need for emergency room physicians who are concerned about the safety risks and cost associated with current imaging techniques.  I am happy to join the Venaxis Board of Directors and look forward to supporting the commercialization of this important diagnostic test and further developing the Venaxis product line.”

Susan A. Evans, Ph.D., FACB brings 30 years of experience in diagnostics and laboratory medicine.  She serves currently as Vice President, Scientific Affairs for the Beckman Coulter division of Danaher Inc.  Dr. Evans has been with Beckman Coulter since 2006, where she held past roles as Vice President, Corporate Strategic Planning and Vice President/General Manager of Beckman Coulter Genomics, known formerly as Agencourt Bioscience.  Prior to her career at Beckman Coulter, Dr. Evans held senior product development and R&D positions at Caliper Life Sciences and LifeScan, respectively.  Dr. Evans began her career in diagnostics at Dade Behring, Inc., where she served in various R&D capacities from 1981 – 2000, eventually assuming a leadership role as Senior Vice President of R&D.  Dr. Evans is also a Past President, Secretary, and member of Board of Directors for the American Association of Clinical Chemistry (AACC), for which she received an award in 2008 for outstanding contributions through service to the profession.  She currently Chairs the Van Slyke Foundation Board of Trustees as well as the Awards Committee for AACC.  Dr. Evans earned a Ph.D. in chemistry from the University of Detroit.

About Venaxis, Inc.

Venaxis, Inc. (formerly known as AspenBio Pharma, Inc.) is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test, APPY1.  The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.venaxis.com.

Forward-Looking Statements

This press release includes “forward-looking statements” of Venaxis, Inc. (“Venaxis”) as defined by the Securities and Exchange Commission (“SEC”). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from APPY1, execute agreements required to successfully advance the company’s objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis’ recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
jrando@tiberend.com

Guanwei Recycling (GPRC) Regains Compliance With NASDAQ

FUQING CITY, CHINA — (Marketwire) — 12/20/12 — Guanwei Recycling Corp. (NASDAQ: GPRC), China’s leading clean tech manufacturer of recycled low density polyethylene (LDPE), today reported the Company has been notified by the Nasdaq Stock Market (“Nasdaq”) that Nasdaq has determined that for the last 10 consecutive business days, from December 5, 2012, through December 18, 2012, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Nasdaq’s Minimum Bid Price Rule.

Description of Guanwei Recycling Corp.

Guanwei Recycling Corp. is China’s largest manufacturer of recycled low density polyethylene (LDPE). Adhering to the highest “green” standards, it has generated rapid growth producing LDPE from plastic waste procured mostly in Europe for sales to more than 300 customers (including over 150 active recurring customers) in more than ten different industries in China. Guanwei Recycling Corp. is one of the few plastic recyclers in China that has been issued a Compliance Certificate by Umweltagentur Erftstadt, which issues certificates of approval for certain plastics manufacturers which meet strict environmental standards in Germany. This enables the Company to procure high quality plastic waste directly from Germany and other European countries (Spain and Holland), with no middlemen, and permits highly economic production of the highest grades of LDPE. Additional information regarding Guanwei Recycling Corp. is available at www.guanweirecycling.com.

Information Regarding Forward-Looking Statements

Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.

Contacts:

Richard Sun
guanweirecycling@gmail.com

Ken Donenfeld
DGI Investor Relations
kdonenfeld@dgiir.com
Tel: 212-425-5700

Saratoga Resources (SARA) Provides Operations and Financial Update

Saratoga Resources, Inc. (NYSE MKT: SARA; the “Company” or “Saratoga”) today provided an update on the status of previously announced operations for the remainder of 2012 as well as guidance with respect to certain anticipated year-end financial metrics.

With respect to the previously announced QQ-209 “Buddy” development well, Saratoga has contracted the Parker 50-B drilling rig, which is currently being mobilized to location, and plans to spud the well this Sunday, December 23. Drilling operations on the Buddy well are expected to be completed by year end.

With respect to the previously announced recompletion operations in Grand Bay Field, operations have been completed and the Company has released the Moncla 118 workover rig. Operations on the MP-47 SL 195 QQ-24 well in Grand Bay Field consisted of a gravel-pack completion of the 29M sand while setting up the 20 sand as a future non gravel-pack completion. The well is expected to be brought on production in the next week. On the GPLD A-191 well in Grand Bay Field, the Company performed diagnostic work and has set a retrievable plug to accommodate future operations pending evaluation of its alternatives to access the associated reserves.

The Company also announced that its projected full year 2012 Discretionary Cash Flow is estimated at $30 million, or approximately $1.00 per share, and that its projected year end cash balance is estimated to be in excess of $32 million.

Management Comments

Mr. Thomas F. Cooke, Chairman and Chief Executive Officer of Saratoga Resources, said, “We are pleased to announce that we have returned to executing our development plan with the recompletion of our MP-47 SL 195 QQ-24 well, which came in under budget and ahead of schedule, and the imminent spud of our QQ-209 “Buddy” development well. In addition, the diagnostics performed on our GPLD A-191 are expected to allow us to develop an appropriate plan to maximize production from the well. As we bring the year to a close, we have returned production to normal operating levels after the shut-ins caused by Hurricane Isaac and once more building cash flow and our cash position. While financial performance for the year and our financial position have been impacted by the effects of Hurricane Isaac, including deferral of production and associated revenues estimated to exceed $7 million and deferral of our development plan and associated production and revenues, we are pleased with these anticipated results, all of which indicate that we are generating positive cash flow from operations and are well positioned to effect our 2013 business plan.”

Non-GAAP Financial Measures

Discretionary Cash Flow and Discretionary Cash Flow Per Share are non-GAAP financial measures.

Discretionary Cash Flow and Discretionary Cash Flow Per Share are supplemental financial measures used by the company’s management and by securities analysts, investors, lenders, rating agencies and others who follow the industry as an indicator of the company’s ability to internally fund exploration and development activities. Discretionary cash flow should not be considered as a substitute for net income, operating income, cash flows from operating activities or any other measure of financial performance or liquidity presented in accordance with generally accepted accounting principles (“GAAP”). Discretionary cash flow excludes some, but not all, items that affect net income and operating income and these measures may vary among other companies. Therefore, the company’s Discretionary Cash Flow or its Discretionary Cash Flow Per Share may not be comparable to similarly titled measures used by other companies.

About Saratoga Resources

Saratoga Resources is an independent exploration and production company with offices in Houston, Texas and Covington, Louisiana. Principal holdings cover 32,119 gross/net acres, mostly held-by-production (all depths), currently located in the transitional coastline and protected in-bay environment on parish and state leases of south Louisiana. Most of the company’s large drilling inventory has multiple pay objectives that range from as shallow as 1,000 feet to the ultra-deep prospects below 20,000 feet in water depths of less than 10 feet. For more information, go to Saratoga’s website at www.saratogaresources.com and sign up for regular updates by clicking on the Updates button.

Forward-Looking Statements

This press release includes certain estimates and other forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “assumes”, “seeks”, “estimates”, “should”, and variations of these words and similar expressions, are intended to identify these forward-looking statements. While we believe these statements are accurate, forward-looking statements are inherently uncertain and we cannot assure you that these expectations will occur and our actual results may be significantly different. These statements by the Company and its management are based on estimates, projections, beliefs and assumptions of management and are not guarantees of future performance. Important factors that could cause actual results to differ from those in the forward-looking statements include the factors described in the “Risk Factors” section of the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update or revise any forward-looking statement based on the occurrence of future events, the receipt of new information, or otherwise.

OCZ Technology (OCZ) Receives Extension to Regain Compliance With NASDAQ

SAN JOSE, CA–(Marketwire – December 20, 2012) – OCZ Technology Group, Inc. (NASDAQ: OCZ), a leading provider of high-performance solid-state drives (SSDs) for computing devices and systems, today announced that the Nasdaq Stock Market (“Nasdaq”) has accepted the Company’s plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) which will permit the continued listing of the Company’s stock on the Nasdaq Capital Markets.

On December 17, 2012, the Company submitted to Nasdaq a plan to regain compliance with the Rule. After reviewing the Company’s plan to regain compliance, Nasdaq granted an exception to enable the Company to regain compliance with the Rule. Under the terms of the exception, on or before February 28, 2013, the Company must file its 10-Q for the period ended August 31, 2012 and all other delinquent periodic reports, as required by the Rule.

About OCZ Technology Group, Inc.
Founded in 2002, San Jose, CA-based OCZ Technology Group, Inc. (OCZ) is a global leader in the design, manufacturing, and distribution of high-performance solid-state storage solutions and premium computer components. Offering a complete spectrum of solid-state drives (SSDs), OCZ provides SSDs in a variety of form factors and interfaces (i.e. PCIe, SAS and SATA) to address a wide range of client and enterprise applications. Having developed firmware and controller platforms, to virtualization and endurance extending technologies, the Company delivers vertically integrated solutions enabling transformational approaches to how digital data is captured, stored, accessed, analyzed and leveraged by customers. For more information, please visit: www.ocztechnology.com.

Forward Looking Statements
Certain statements in this release relate to future events and expectations and as such constitute forward-looking statements involving known and unknown factors that may cause actual results of OCZ Technology Group, Inc. to be different from those expressed or implied in the forward-looking statements. In this context, words such as “will,” “would,” “expect,” “anticipate,” “should” or other similar words and phrases often identify forward-looking statements made on behalf of OCZ. It is important to note that actual results of OCZ may differ materially from those described or implied in such forward-looking statements based on a number of factors and uncertainties, including, but not limited to, the risk that additional information may arise from the oversight of the Audit Committee; the risk that the process of preparing and auditing the financial statements or other subsequent events would require OCZ to make additional adjustments; the time and effort required to complete the restatement of the financial reports; the ramifications of OCZ’s potential inability to timely file required reports; including potential delisting of OCZ’s common stock on NASDAQ; the risk of litigation or governmental investigations or proceedings relating to such matters; the risk that OCZ may not be able to successfully negotiate an amendment to its credit facility; market acceptance of OCZ’s products and OCZ’s ability to continually develop enhanced products; adverse changes both in the general macro-economic environment as well as in the industries OCZ serves, including computer manufacturing, traditional and online retailers, information storage, internet search and content providers and computer system integrators; OCZ’s ability to efficiently manage material and inventory, including integrated circuit chip costs and freight costs; and OCZ’s ability to generate cash from operations, secure external funding for its operations and manage its liquidity needs. Other general economic, business and financing conditions and factors are described in more detail in “Item 1A — Risk Factors” in Part I in OCZ’s Annual Report on Form 10-K filed with the SEC on May 14, 2012, and statements made in other subsequent filings. The filing is available both at www.sec.gov as well as via OCZ’s website at www.ocztechnology.com. OCZ does not undertake to update its forward-looking statements.

All trademarks or brand names referred to herein are the property of their respective owners.

Investor Contact:
Bonnie Mott
Senior Manager of Investor Relations
(408) 440-3428
bmott@ocztechnology.com

Press Contact:
Scott Harlin
Director of Marketing Communications – Enterprise
(408) 733-8400
sharlin@ocztechnology.com

Sino-Global (SINO) Announces Establishment of A Wholly-owned Canadian Subsidiary

– New Subsidiary will Provide Services for Ships Loading Commodities at Canadian Ports and Delivering them to China –

BEIJING, Dec. 19, 2012 /PRNewswire/ —Sino-Global Shipping America, Ltd. (Nasdaq: SINO), a leading non-state-owned provider of shipping agency services operating primarily in China, today announced that it has established a new wholly-owned subsidiary, Sino-Global Shipping Canada Inc., to provide services for ships loading commodities at Canadian ports and delivering them to China.

Sino-Global Shipping Canada is already providing shipping services to Baosteel’s vessels in Canada. Baosteel, based in Shanghai, China, is the second largest steel producer in the world with huge demands for iron ore and other commodities.

Mr. Cao Lei, Sino-Global’s Chief Executive Officer, stated, “As we have noted in the past, Sino- Global Shipping America Ltd. has always sought to expand its geographical reach by developing relationships and activities worldwide. The new wholly-owned Canadian subsidiary is another step in establishing Sino-Global as the pre-eminent provider of shipping services worldwide. Canada is a country rich in natural resources and is a major shipper of such commodities throughout the world.  We anticipate that Sino-Global Shipping Canada will open up additional Canadian business opportunities that will result in incremental revenues and earnings.

About Sino-Global Shipping America, Ltd.

Registered in the United States in 2001 and operating primarily in mainland China, Sino-Global is a leading, non-state-owned provider of high-quality shipping agency services. With local branches in most of China’s main ports and contractual arrangements in all those where it does not have branch offices, Sino-Global is able to offer efficient, high-quality shipping agency services to shipping companies entering Chinese ports. With a subsidiary in Perth, Australia, where it has a contractual relationship with a local shipping agency, Sino-Global provides complete shipping agent services to companies involved in trades between Chinese and Australian ports. Sino-Global also cooperates with companies in Hong Kong, China, India, and South Africa to offer comprehensive shipping agent services to vessels going to and from some of the world’s busiest ports.

Sino-Global provides ship owners, operators and charters with comprehensive yet customized shipping agency services including intelligence, planning, real-time analysis and on-the-ground implementation and logistics support. Sino-Global has achieved both ISO9001 and UKAS certifications.

Forward Looking Statements

No statement made in this press release should be interpreted as an offer to purchase any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in Sino-Global’s filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. Sino-Global undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

For More Information

For a more detailed review of Sino-Global, please refer to Sino-Global’s web site: www.sino-global.com

CONTACTS:

Smart Investors Spot Profitable Upside in Neptune’s (NEPT) Recovery Plan

LOS ANGELES, CA — (Marketwire) — 12/19/12 — Neptune Technologies & Bioresources, Inc. (NASDAQ: NEPT) has seen its stock fall 45% from its closing price on November 7th. On December 8th, Neptune suffered a tragedy, in which their manufacturing facility and inventory were completely destroyed in an explosion that also took the lives of 3 of their employees and injured several others. The tragic explosion has left the Company without manufacturing facilities and inventory of their flagship Neptune Krill Oil product. Neptune’s stock price has been falling since and the rate of decline has accelerated in the last few days. On November 26th, Neptune put out an action plan which management will use as a guideline for returning to normalized business. With the stock down significantly and the management fighting hard for the future of the Company the question investors find themselves asking is can Neptune recover?

Contrary to some recent positions, Neptune is anything but dead in the water. Investors should look at the business from today forward. If investors take an inventory, they will see that the Company has many valuable assets, plenty of cash on hand, two pharmaceutical subsidiaries, and a plan to move forward from the tragedy to rebuild an efficient, growing and profitable business. Neptune’s core business, krill oil neutraceuticals, is a growing business that has a large and growing market, growing 70% in 2012 by some estimates, and has been a profitable business segment for Neptune for the last three years.

Below are the key points from Neptune’s recently unveiled Action Plan:

1. Resuming its neutraceutical operations and certain levels of sales of its Neptune Krill Oil® products to customers in the short term;

2. Maintaining key customer relationships and market share, particularly until production of Neptune Krill Oil® products can reach pre-incident levels;

3. Reconstructing an operational plant using the expansion facility that was under completion and certain existing equipment in the expansion, which expansion and equipment do not appear to have suffered considerable damages from the incident;

4. Pursuing partnerships and/or arrangements with one or more strategic partners for the outsourcing of production for Neptune Krill Oil® products, both as an interim measure to ensure certain levels of production prior to its new plant being fully operational and as a longer-term strategy to diversify sources and means of production; and

5. Prudently managing its financial resources while continuing its product development and clinical trials, including defending its patents and intellectual property and supporting as planned the pharmaceutical development of its two subsidiaries, Acasti Pharma Inc. (“Acasti“) and NeuroBioPharm Inc. (“NeuroBio“), whose operations have not been interrupted as a result of the incident.

Looking at the Action Plan there are many details that need to be addressed to make it successful. The primary issue is how to serve their customer base, maintain market share and customers while the rebuilding is taking place. The rebuilding of the manufacturing facility is key. In a conversation with the management we asked the important question of not just how long, but what is actually in place? Neptune was in the process of expanding the Sherbrooke manufacturing facility when the accident occurred. The facility was about 8 weeks from coming on line. This first expansion was planned to be a doubling of the capacity of the plant from 150,000kg/year to 300,000kg/year. A second expansion was to take the plant to 500,000kg/year. The fact is that the production line of the first expansion was completed. What this new facility had was the back-end of the process in the manufacturing; this line was to be supplied by the existing front-end process, which is the extraction process. The front-end of the operation was destroyed. Neptune is on their way to building the new front-end processing, with machinery ordered and plenty of space available in the expansion facility. The back-end process equipment already in place is more sophisticated, costly and time consuming equipment, which gives the management confidence they can have the Sherbrooke plant back up and operational in the previously stated six months. The bottom line on the plant is that much of it is already in place.

Going back to the plan, items 1, 2, and 4 can be grouped together. This goes back to the question of how to serve the customer base and maintain market share and customers during the six months until Sherbrooke is operational. Management has been active in the development of potential manufacturing partners. These potential partners have been identified and management has engaged in discussions. Management’s job number one in these discussions is to find available capacity and supply their current customer base and fulfill the current orders. Due to fulfilling these orders on short notice through other suppliers, Neptune will be able to maintain their revenues, but the margins will be greatly reduced for at least two quarters. The important fact is Neptune should be able to continue its business with minimal issues for their customers until Sherbrooke is ready to go.

A benefit of this process is Neptune will have access to multiple suppliers of their formulation of Neptune Krill Oil (NKO). In the long run, not only will Neptune have the safety of supply diversification, but they will have the potential to outsource the majority of their manufacturing needs. Neptune will be able to focus on product development, intellectual property development, marketing and the pharmaceutical subsidiaries, while decreasing overall cost and expanding margins. These relationships may also make the next planned expansion of Sherbrooke to 500,000kg/year unnecessary, saving Neptune up to $5 million of dollars in capital expenditures (according to the October 3rd funding use of proceeds). At the very least these future partners will alleviate the need for further expansions beyond the 500,000kg/year planned expansion. In 2004 when Neptune began producing NKO, there were no producers from which to acquire outsourced product and Neptune had to build their own manufacturing facilities. Now, just over 8 years later, there are many manufacturers willing to go into krill oil manufacturing as krill oil has established a growing global market.

Item number 5 in the action plan has many facets. “Prudently managing its financial resources,” pretty much sums it up. On October 2nd Neptune announced the closing of a $34.1 million financing that was led by RBC Capital Markets and JMP Securities, two well-respected brokerage firms. The investors in the offering were primarily institutional investors. The current cash position per share is $0.70/share. This is a significant amount of cash to have on hand to bridge the six months until the manufacturing factory reopens. On top of that, the Company also has both property damage and business interruption insurance. In an article released by Reuters, André Godin, CFO of Neptune, stated that the factory was insured for about $20 million and the money would be used to optimize the existing expansion facility at Sherbrooke. Mr. Godin went on to say that the factory would come online in about six months. The business interruption insurance will provide some compensation to the company to help cover losses incurred from the immediate outsourcing needs. These two insurance policies will help limit the impact on the shareholders from this accident, to some extent.

Item five also discusses “continuing its product development and clinical trials, including defending its patents and intellectual property and supporting as planned the pharmaceutical development of its two subsidiaries, Acasti Pharma Inc. (‘Acasti‘) and NeuroBioPharm Inc. (‘NeuroBio‘).” These are important issues as it signifies it is still business as usual for the rest of the Company and its subsidiaries. These items mentioned are also valuation creators for Neptune, as all are important assets to the Company. A proper valuation analysis, which is not the purpose of this article, would show that the intellectual property of Neptune has substantial value, as the Company has successfully defended and proven the IP’s viability and worth in court several times against competitors’ claims.

More importantly, Acasti Parma Inc. just released interim data on its Phase II double blinded, placebo controlled clinical study for CaPre®. The data showed a statistically significant 25% (p < 0.05) reduction in triglycerides after eight weeks of treatment in 19 patients with baseline triglyceride levels between 204 and 476mg/dl. CaPre® also decreased Low Density Lipoprotein (LDL), Very Low Density Lipoprotein (VLDL) and non-HDL lipids and increased High Density Lipoprotein (HDL). This news increases the value of Acasti, and as a stand-alone it is possible that Acasti is worth more than the current market cap of Neptune.

The facts are simple; Neptune will have the Sherbrook up and running in about six months. The Company should be able to maintain supplies to customers and maintain revenues for a business segment that has been profitable for 3 years. Neptune has valuable assets; plenty of cash and the losses will be offset to some extent by insurance further preserving shareholder value. When the plant reopens, Neptune should be able to produce nearly as much in revenues as the September quarter. The Company will have new manufacturing partners, and there will be no constraints holding back Neptune from growing as much as their marketing efforts will allow. Acasti Pharma will be further along in its Phase II and preparing for its Phase III.

Shortly after Sherbrooke restarts, Neptune overall will be farther ahead as a business than they were when the accident occurred, with a more efficient structure. Neptune could also be more valuable if management executes on its plan. Some of the current institutional investors have acknowledged, for this article, that they are buyers of the stock at these levels and other are watching closely for potential entry points into the stock. Neptune had a market cap of around $250 million, and was growing, at the time the funding in October, and now the Company has a market cap of $100 million. We see a path for the Company to again produce at the sales and margin levels of the September quarter beginning in about six months, and it is possible for Neptune to reclaim its lost value over the course of the next 12 months. There is still some execution risk and the stock is speculative, but Neptune has too many assets not to further investigate the potential of investing in Neptune based upon the real facts of this Company. It is reasonable to conclude that the stock price can return to levels prior to the accident over the course of the next 12 months, which would be a very attractive potential ROI for investors from the previous closing price of $1.71/share.

The full report including charts and technical analysis is available at:

http://www.biomedreports.com/20121219117021/smart-investors-spot-clear-upside-in-neptunes-recovery-action-plan.html

Healthcare investors and Biotech traders interested in accessing BioMedReports’ new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html

Follow Us

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com

Add to Digg Bookmark with del.icio.us Add to Newsvine

Media Contacts Only:
M. Davila
Assistant Editor
BioMedReports.Com

Idera (IDRA) Announces Positive Top-line Results from Phase 2 Plaque Psoriasis Trial

Idera Pharmaceuticals Announces Positive Top-line Results from Phase 2 Trial of IMO-3100 in Patients with Moderate-to-Severe Plaque Psoriasis

Idera Pharmaceuticals (NASDAQ: IDRA) today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period. None of the 12 placebo-treated patients had improvement in this range; this difference was statistically significant (p<0.005). The Company believes the results of this trial provide clinical proof-of-concept for the mechanism of action of selective TLR inhibition in patients with psoriasis and potentially other autoimmune and inflammatory disorders.

“The clinical activity of IMO-3100 demonstrated in patients with moderate-to-severe plaque psoriasis is encouraging, especially given the short duration of treatment in this study that was designed for initial explorations of safety and efficacy,” commented Alexa Kimball, M.D., M.P.H., Vice Chair, Department of Dermatology at Massachusetts General Hospital, Boston, and an investigator in the trial.

“The achievement of statistically significant PASI reductions with only four weeks of treatment in a placebo-controlled double-blind trial directly supports the rationale that the modulation of specific TLRs plays a key role in the treatment of psoriasis and, potentially, other autoimmune and inflammatory disorders,” commented James Krueger, M.D., Ph.D., of The Rockefeller University, New York. “We are excited to see these data, which demonstrate the translation of targeting a novel mechanism of action into clinical activity and support further studies of TLR antagonists for the treatment of psoriasis. Our laboratory is continuing to evaluate the immunological pathways by which TLR antagonists suppress the signaling cascades that underlie psoriasis and have the potential to open up a new approach to disease treatment.”

About the IMO-3100 Phase 2 Trial in Psoriasis

The Phase 2 trial was a randomized, double-blind, placebo-controlled trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. In the trial, 44 patients were randomized to receive IMO-3100 monotherapy at 0.16 or 0.32 mg/kg or placebo by subcutaneous injection once weekly for four weeks with four weeks of follow-up. Assessments of safety were performed throughout the treatment and follow-up periods. Multiple parameters were monitored to assess the clinical activity of IMO-3100, including Psoriasis Area Severity Index (PASI), mean focal psoriasis severity and Physician Global Assessment (PGA) scores. In addition to the clinical assessments, biopsies of psoriasis plaques were evaluated for treatment-related changes in epidermal thickness and immune cell infiltrates consistent with the intended mechanism of action. Patients were enrolled at eleven sites in the United States.

Top-line clinical results from this trial include:

• Of the 44 enrolled patients, 40 were clinically evaluable at the end of the four-week treatment period and 37 were evaluable following the four-week follow up period
• Treatment at both IMO-3100 dose levels was well tolerated, with no treatment-related discontinuations
• Among evaluable patients, the median PASI scores at treatment initiation were 14.9, 16.1, and 12.5 in the 0.16 mg/kg, 0.32 mg/kg, and placebo cohorts, respectively
• A treatment effect was demonstrated in measures of clinical efficacy in patients in both IMO-3100 dose cohorts; PASI reductions at both dose levels were sustained throughout the four-week follow-up period
• At the end of the four-week follow-up period, 48% of patients treated with either dose of IMO-3100 (12 of 25) demonstrated improvements of 35% to 90% from baseline PASI scores compared with 0 of 12 in the placebo cohort; this difference was statistically significant (p<0.005)
• The trial achieved the pre-specified clinical endpoint of reduction in PASI scores at the end of treatment in the 0.16 mg/kg dose cohort with statistical significance (p<0.02) compared to the placebo cohort, but not in the 0.32 mg/kg dose cohort
• The 0.16 mg/kg cohort also achieved, with statistical significance (p<0.02), the pre-specified clinical endpoint of improvement in induration, a measure of plaque thickness, at the end of treatment and during the follow-up period
• At the end of the four-week follow-up period, 25% (3 of 12) of patients treated with 0.16 mg/kg dose and 31% (4 of 13) with 0.32 mg/kg dose achieved PASI 50 or greater, compared to 0 of 12 placebo patients

Skin biopsies were collected at baseline and after completion of treatment to investigate changes in epidermal thickness and immune cell infiltrates. Change in epidermal thickness was the primary endpoint for the trial. Placebo treated patients had a median change in epidermal thickness of +7.7% compared to a median change of -6.4% among IMO-3100 treated patients; this difference was not statistically significant. A known limitation of skin biopsies after four weeks of treatment is that psoriatic plaques do not resolve in a uniform fashion, and therefore, biopsies may not provide a representative sampling of lesions (ref: Ann Rheum Dis 2005;64:65-68).

The Company plans to present complete clinical data from this trial at an upcoming medical meeting.

“We believe this trial in patients with moderate-to-severe plaque psoriasis provides clinical proof-of-concept for this first-in-class TLR antagonist, which represents a novel approach to the treatment of autoimmune diseases. We are very pleased to have observed clinical responses after only four weeks of treatment,” stated Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera. “The insights gained from this trial support expansion of our TLR antagonist program for the treatment of autoimmune diseases. In 2013, we plan to advance the clinical development of a selective TLR antagonist for the treatment of moderate-to-severe plaque psoriasis and also for the treatment of lupus.”

About TLRs and Idera’s Pipeline

Toll-like Receptors (TLRs) play a key role in inflammation and immunity. Of the 10 human TLRs identified to date, Idera is developing compounds targeted to TLRs 3, 7, 8 and 9, which are expressed in different cells and serve unique functions. Using its chemistry-based approach, Idera has created novel drug candidates that modulate immune responses through either activation or inhibition of specific TLRs. Inhibition of specific TLRs may be useful in treating autoimmune disorders, such as systemic lupus erythematosus (SLE), psoriasis and rheumatoid arthritis, by blocking the induction of multiple cytokines and signaling pathways. Idera’s clinical candidates for application in autoimmune diseases are IMO-3100, an antagonist of TLR7 and TLR9, and IMO-8400, an antagonist of TLRs 7, 8 and 9.

A characteristic of autoimmune diseases such as SLE and psoriasis is the production of immune complexes with self-nucleic acids. These abnormal immune complexes activate TLRs 7, 8 and 9 and induce multiple cytokines that cause further damage to the body’s own tissues and organs, thereby releasing more self-nucleic acids. Thus, a pathologic amplification cycle is established, promoting disease maintenance and progression. In preclinical models of several autoimmune diseases, IMO-3100 and IMO-8400 inhibited TLR-mediated immune responses, interrupted the cycle of disease maintenance and progression through decreases in Th1, Th17 and inflammasome pathways, and led to improvements in multiple measures of disease.

About IMO-3100

IMO-3100, an antagonist of TLR7 and TLR9, is a lead drug candidate in development to treat autoimmune diseases, including psoriasis. In preclinical mouse models of psoriasis, IMO-3100 exerted therapeutic activity by inhibiting disease-associated gene expression and cytokines, such as IL-6, IL-22, IL-17, IL-23, NLRP3 and IL-1β, and proteins in the skin such as S100A7, DEFB4 and LL37. In addition, histological evaluation showed that the psoriatic lesions in IMO-3100-treated animals had reduced epidermal thickness and decreased lymphocyte infiltration compared to control mice.

About Psoriasis

Psoriasis is a systemic immune-mediated disorder, characterized by inflammatory skin and joint manifestations. The most common form, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells. Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes, heart disease and depression.

Psoriasis is the most prevalent autoimmune disease in the U.S., according to the National Psoriasis Foundation, affecting as many as 7.5 million Americans.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has a clinical development program in autoimmune diseases. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. The Company is also exploring its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. For more information, visit http://www.iderapharma.com.

Idera Forward Looking Statements

This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “should,” “could,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera’s actual results to differ materially from those indicated by such forward-looking statements, including whether Idera’s cash resources will be sufficient to fund the Company’s continuing operations and the further development of the Company’s autoimmune disease program; whether results obtained in preclinical studies and early clinical trials, such as the results from the Phase 2 trial and the preclinical studies referred to in this release, will be indicative of results obtained in future clinical trials; whether products based on Idera’s technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company’s products receive approval, they will be successfully distributed and marketed; whether the Company will be able to license any of its TLR target candidates on a timely basis or at all; whether the Company’s collaboration with Merck & Co, Inc., will be successful; whether the patents and patent applications owned or licensed by the Company will protect the Company’s technology and prevent others from infringing it; and such other important factors as are set forth under the caption “Risk Factors” in Idera’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.

Dynatronics (DYNT) Announces Reverse Stock Split

SALT LAKE CITY, Dec. 19, 2012 /PRNewswire/ — Dynatronics Corporation (Nasdaq: DYNT) today announced that on December 17, 2012, at the Company’s annual meeting, the shareholders approved a one-for-five reverse stock split of the Company’s common stock.  Approximately 93% of the votes cast were in favor of the reverse split which becomes effective today.

“After careful analysis, our board of directors determined that the best course of action for shareholders was to maintain our Nasdaq listing where we have traded for the past 28 years,” stated Kelvyn H. Cullimore, Jr., chairman and president of Dynatronics.  “Our research showed that staying on Nasdaq provides greater liquidity through higher trading volumes, as well as tighter spreads between bid and ask prices, more market makers and overall better investor confidence compared to trading in the over-the-counter market as a result of being delisted from Nasdaq.”

The Company has a number of positive developments which management believes should bode well for the Company’s future performance.  “This week, we are completing the expansion of our California operation into a new, larger facility in Livermore, CA to better serve our west coast customers,” reported Cullimore.   “Beginning today, we will be operating from that new facility which will allow greater operating efficiencies than our previous facility.  In addition, our new SolarisPlus line of therapy devices is being well received by the market.  October was a very profitable month for the Company and should result in earnings for the quarter ended December 31^st improving significantly over the same period last year.”

The Company is also working on expanding its distribution channels over the coming quarters and will introduce a record number of new products in fiscal year 2013.  “We expect these expansion plans and new product introductions to lead us to higher profits in the coming year,” he added.

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company’s expectations and similar statements such as the statement regarding expectations relating to share trading volume, operating efficiencies, future profitability, market acceptance of new products, and future operating results and growth. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company’s products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company’s products, availability of financing at cost-effective rates, and the risk factors listed from time to time in the company’s SEC reports.  The Company expressly disclaims any obligation or intention to update any forward-looking statement contained in this release.